**ANNEX I**

SUMMARY OF PRODUCT CHARACTERISTICS

**1. NAME OF THE MEDICINAL PRODUCT**

Aerius 5 mg film-coated tablets

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each tablet contains 5 mg desloratadine.

Excipient(s) with known effect:

This medicine contains lactose.

For the full list of excipients, see section 6.1.

**3. PHARMACEUTICAL FORM**

Film-coated tablets

**4. CLINICAL PARTICULARS**

**4.1 Therapeutic indications**

Aerius is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with:

* allergic rhinitis (see section 5.1)
* urticaria (see section 5.1)

**4.2 Posology and method of administration**

Posology

*Adults and adolescents (12 years of age and over)*

The recommended dose of Aerius is one tablet once a day.

Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient’s disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance.

In persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks), continued treatment may be proposed to the patients during the allergen exposure periods.

*Paediatric population*

There is limited clinical trial efficacy experience with the use of desloratadine in adolescents 12 through 17 years of age (see sections 4.8 and 5.1).

The safety and efficacy of Aerius 5 mg film-coated tablets in children below the age of 12 years have not been established.

Method of administration

Oral use.

The dose can be taken with or without food.

**4.3 Contraindications**

Hypersensitivity to the active substance, to any of the excipients listed in section 6.1, or to loratadine.

**4.4 Special warnings and precautions for use**

In the case of severe renal insufficiency, Aerius should be used with caution (see section 5.2).

Desloratadine should be administered with caution in patients with medical or familial history of seizures, and mainly young children (see section 4.8), being more susceptible to develop new seizures under desloratadine treatment. Healthcare providers may consider discontinuing desloratadine in patients who experience a seizure while on treatment.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

**4.5 Interaction with other medicinal products and other forms of interaction**

No clinically relevant interactions were observed in clinical trials with desloratadine tablets in which erythromycin or ketoconazole were co-administered (see section 5.1).

Paediatric population

Interaction studies have only been performed in adults.

In a clinical pharmacology trial, Aerius tablets taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol (see section 5.1). However, cases of alcohol intolerance and intoxication have been reported during post‑marketing use. Therefore, caution is recommended if alcohol is taken concomitantly.

**4.6 Fertility, pregnancy and lactation**

Pregnancy

A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no malformative nor foeto/ neonatal toxicity of desloratadine. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of Aerius during pregnancy.

Breast-feeding

Desloratadine has been identified in breastfed newborns/infants of treated women. The effect of desloratadine on newborns/infants is unknown. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Aerius therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

Fertility

There are no data available on male and female fertility.

**4.7 Effects on ability to drive and use machines**

Aerius has no or negligible influence on the ability to drive and use machines based on clinical trials. Patients should be informed that most people do not experience drowsiness. Nevertheless, as there is individual variation in response to all medicinal products, it is recommended that patients are advised not to engage in activities requiring mental alertness, such as driving a car or using machines, until they have established their own response to the medicinal product.

**4.8 Undesirable effects**

Summary of the safety profile

In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Aerius were reported in 3 % of patients in excess of those treated with placebo. The most frequent of adverse reactions reported in excess of placebo were fatigue (1.2 %), dry mouth (0.8 %) and headache (0.6 %).

Paediatric population

In a clinical trial with 578 adolescent patients, 12 through 17 years of age, the most common adverse event was headache; this occurred in 5.9 % of patients treated with desloratadine and 6.9 % of patients receiving placebo.

Tabulated list of adverse reactions

The frequency of the clinical trial adverse reactions reported in excess of placebo and other undesirable effects reported during the post-marketing period are listed in the following table. Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).

| **System Organ Class** | **Frequency** | **Adverse reactions seen with Aerius** |
| --- | --- | --- |
| **Metabolism and nutrition disorders** | Not known | Increased appetite |
| **Psychiatric disorders** | Very rare  Not known | Hallucinations  Abnormal behaviour, aggression |
| **Nervous system disorders** | Common  Very rare | Headache  Dizziness, somnolence, insomnia, psychomotor hyperactivity, seizures |
| **Cardiac disorders** | Very rare  Not known | Tachycardia, palpitations  QT prolongation |
| **Gastrointestinal disorders** | Common  Very rare | Dry mouth  Abdominal pain, nausea, vomiting, dyspepsia, diarrhoea |
| **Hepatobiliary disorders** | Very rare  Not known | Elevations of liver enzymes, increased bilirubin, hepatitis  Jaundice |
| **Skin and subcutaneous tissue disorders** | Not known | Photosensitivity |
| **Musculoskeletal and connective tissue disorders** | Very rare | Myalgia |
| **General disorders and administration site conditions** | Common  Very rare  Not known | Fatigue  Hypersensitivity reactions (such as anaphylaxis, angioedema, dyspnoea, pruritus, rash, and urticaria)  Asthenia |
| **Investigations** | Not known | Weight increased |

Paediatric population

Other undesirable effects reported during the post‑marketing period in paediatric patients with an unknown frequency included QT prolongation, arrhythmia, bradycardia, abnormal behaviour, and aggression.

A retrospective observational safety study indicated an increased incidence of new-onset seizure in patients 0 to 19 years of age when receiving desloratadine compared with periods not receiving desloratadine. Among children 0-4 years old, the adjusted absolute increase was 37.5 (95% Confidence Interval (CI) 10.5-64.5) per 100,000 person years (PY) with a background rate of new onset seizure of 80.3 per 100,000 PY. Among patients 5-19 years of age, the adjusted absolute increase was 11.3 (95% CI 2.3-20.2) per 100,000 PY with a background rate of 36.4 per 100,000 PY. (See section 4.4.)

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc).

**4.9 Overdose**

The adverse event profile associated with overdosage, as seen during post‑marketing use, is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher.

Treatment

In the event of overdose, consider standard measures to remove unabsorbed active substance. Symptomatic and supportive treatment is recommended.

Desloratadine is not eliminated by haemodialysis; it is not known if it is eliminated by peritoneal dialysis.

Symptoms

Based on a multiple dose clinical trial, in which up to 45 mg of desloratadine was administered (nine times the clinical dose), no clinically relevant effects were observed.

Paediatric population

The adverse event profile associated with overdosage, as seen during post‑marketing use, is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: antihistamines – H1 antagonist, ATC code: R06A X27

Mechanism of action

Desloratadine is a non-sedating, long-acting histamine antagonist with selective peripheral H1-receptor antagonist activity. After oral administration, desloratadine selectively blocks peripheral histamine H1-receptors because the substance is excluded from entry to the central nervous system.

Desloratadine has demonstrated antiallergic properties from *in vitro* studies.These include inhibiting the release of proinflammatory cytokines such as IL-4, IL-6, IL-8, and IL-13 from human mast cells/basophils, as well as inhibition of the expression of the adhesion molecule P-selectin on endothelial cells. The clinical relevance of these observations remains to be confirmed.

Clinical efficacy and safety

In a multiple dose clinical trial, in which up to 20 mg of desloratadine was administered daily for 14 days, no statistically or clinically relevant cardiovascular effect was observed. In a clinical pharmacology trial, in which desloratadine was administered at a dose of 45 mg daily (nine times the clinical dose) for ten days, no prolongation of QTc interval was seen.

No clinically relevant changes in desloratadine plasma concentrations were observed in multiple-dose ketoconazole and erythromycin interaction trials.

Desloratadine does not readily penetrate the central nervous system. In controlled clinical trials, at the recommended dose of 5 mg daily, there was no excess incidence of somnolence as compared to placebo. Aerius given at a single daily dose of 7.5 mg did not affect psychomotor performance in clinical trials. In a single dose study performed in adults, desloratadine 5 mg did not affect standard measures of flight performance including exacerbation of subjective sleepiness or tasks related to flying.

In clinical pharmacology trials, co-administration with alcohol did not increase the alcohol-induced impairment in performance or increase in sleepiness. No significant differences were found in the psychomotor test results between desloratadine and placebo groups, whether administered alone or with alcohol.

In patients with allergic rhinitis, Aerius was effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate. Aerius effectively controlled symptoms for 24 hours.

Paediatric population

The efficacy of Aerius tablets has not been clearly demonstrated in trials with adolescent patients 12 through 17 years of age.

In addition to the established classifications of seasonal and perennial, allergic rhinitis can alternatively be classified as intermittent allergic rhinitis and persistent allergic rhinitis according to the duration of symptoms. Intermittent allergic rhinitis is defined as the presence of symptoms for less than 4 days per week or for less than 4 weeks. Persistent allergic rhinitis is defined as the presence of symptoms for 4 days or more per week and for more than 4 weeks.

Aerius was effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire. The greatest amelioration was seen in the domains of practical problems and daily activities limited by symptoms.

Chronic idiopathic urticaria was studied as a clinical model for urticarial conditions, since the underlying pathophysiology is similar, regardless of etiology, and because chronic patients can be more easily recruited prospectively. Since histamine release is a causal factor in all urticarial diseases, desloratadine is expected to be effective in providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathic urticaria, as advised in clinical guidelines.

In two placebo-controlled six week trials in patients with chronic idiopathic urticaria, Aerius was effective in relieving pruritus and decreasing the size and number of hives by the end of the first dosing interval. In each trial, the effects were sustained over the 24 hour dosing interval. As with other antihistamine trials in chronic idiopathic urticaria, the minority of patients who were identified as non-responsive to antihistamines was excluded. An improvement in pruritus of more than 50 % was observed in 55 % of patients treated with desloratadine compared with 19 % of patients treated with placebo. Treatment with Aerius also significantly reduced interference with sleep and daytime function, as measured by a four-point scale used to assess these variables.

**5.2 Pharmacokinetic properties**

Absorption

Desloratadine plasma concentrations can be detected within 30 minutes of administration. Desloratadine is well absorbed with maximum concentration achieved after approximately 3 hours; the terminal phase half-life is approximately 27 hours. The degree of accumulation of desloratadine was consistent with its half-life (approximately 27 hours) and a once daily dosing frequency. The bioavailability of desloratadine was dose proportional over the range of 5 mg to 20 mg.

In a pharmacokinetic trial in which patient demographics were comparable to those of the general seasonal allergic rhinitis population, 4 % of the subjects achieved a higher concentration of desloratadine. This percentage may vary according to ethnic background. Maximum desloratadine concentration was about 3-fold higher at approximately 7 hours with a terminal phase half-life of approximately 89 hours. The safety profile of these subjects was not different from that of the general population.

Distribution

Desloratadine is moderately bound (83 % - 87 %) to plasma proteins. There is no evidence of clinically relevant medicine accumulation following once daily dosing of desloratadine (5 mg to 20 mg) for 14 days.

Biotransformation

The enzyme responsible for the metabolism of desloratadine has not been identified yet, and therefore, some interactions with other medicinal products cannot be fully excluded. Desloratadine does not inhibit CYP3A4 *in vivo,* and *in vitro* studies have shown that the medicinal product does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein.

Elimination

In a single dose trial using a 7.5 mg dose of desloratadine, there was no effect of food (high-fat, high caloric breakfast) on the disposition of desloratadine. In another study, grapefruit juice had no effect on the disposition of desloratadine.

Renally impaired patients

The pharmacokinetics of desloratadine in patients with chronic renal insufficiency (CRI) was compared with that of healthy subjects in one single‑dose study and one multiple dose study. In the single‑dose study, the exposure to desloratadine was approximately 2 and 2.5‑fold greater in subjects with mild to moderate and severe CRI, respectively, than in healthy subjects. In the multiple‑dose study, steady state was reached after Day 11, and compared to healthy subjects the exposure to desloratadine was ~1.5‑fold greater in subjects with mild to moderate CRI and ~2.5‑fold greater in subjects with severe CRI. In both studies, changes in exposure (AUC and Cmax) of desloratadine and 3‑hydroxydesloratadine were not clinically relevant.

**5.3 Preclinical safety data**

Desloratadine is the primary active metabolite of loratadine. Non-clinical studies conducted with desloratadine and loratadine demonstrated that there are no qualitative or quantitative differences in the toxicity profile of desloratadine and loratadine at comparable levels of exposure to desloratadine.

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. The lack of carcinogenic potential was demonstrated in studies conducted with desloratadine and loratadine.

**6. PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

Tablet core: calcium hydrogen phosphate dihydrate, microcrystalline cellulose, maize starch, talc.

Tablet coating: film coat (containing lactose monohydrate, hypromellose, titanium dioxide, macrogol 400, indigotin (E132)), clear coat (containing hypromellose, macrogol 400), carnauba wax, white wax.

**6.2 Incompatibilities**

Not applicable.

**6.3 Shelf life**

2 years

**6.4 Special precautions for storage**

Do not store above 30°C.

Store in the original package.

**6.5 Nature and contents of container**

Aerius is supplied in blisters comprised of laminate blister film with foil lidding.

The materials of the blister consist of a polychlorotrifluoroethylene (PCTFE)/Polyvinyl Chloride (PVC) film (product contact surface) with an aluminium foil lidding coated with a vinyl heat seal coat (product contact surface) which is heat sealed.

Packs of 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50, 90, 100 tablets.

Not all pack sizes may be marketed.

**6.6 Special precautions for disposal**

No special requirements.

**7. MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.

Waarderweg 39

2031 BN Haarlem

The Netherlands

**8. MARKETING AUTHORISATION NUMBERS**

EU/1/00/160/001-013

EU/1/00/160/036

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 15 January 2001

Date of latest renewal: 15 January 2006

**10. DATE OF REVISION OF THE TEXT**

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.

**1. NAME OF THE MEDICINAL PRODUCT**

Aerius 2.5 mg orodispersible tablets

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each orodispersible tablet contains 2.5 mg desloratadine.

Excipient(s) with known effect:

This medicine contains mannitol and aspartame (E951).

For the full list of excipients, see section 6.1.

**3. PHARMACEUTICAL FORM**

Orodispersible tablet

Light-red, flat-faced, round, speckled tablets, one side branded with “K”

**4. CLINICAL PARTICULARS**

**4.1 Therapeutic indications**

Aerius is indicated in adults, adolescents aged 12 years and older and children aged 6 – 11 years old for the relief of symptoms associated with:

* allergic rhinitis (see section 5.1)
* urticaria (see section 5.1)

**4.2 Posology and method of administration**

Posology

*Adults and adolescents (12* *years of age and over)*

The recommended dose of Aerius is two 2.5 mg orodispersible tablets placed in the mouth once a day.

*Paediatric population*

Children 6 to 11 years of age: the recommended dose of Aerius is one 2.5 mg orodispersible tablet placed in mouth once a day.

The safety and efficacy of Aerius 2.5 mg orodispersible tablets in children below the age of 6 years have not been established.

There is limited clinical trial efficacy experience with the use of desloratadine in children 6 through 11 years of age (see section 5.2).

There is limited clinical trial efficacy experience with the use of desloratadine in adolescents 12 through 17 years of age (see sections 4.8 and 5.1).

Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient’s disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance. In persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks), continued treatment may be proposed to the patients during the allergen exposure periods.

Method of administration

Oral use.

The dose can be taken with or without food.

Immediately before use, the blister must be carefully peeled open and the dose of orodispersible tablet removed without crushing it. The dose of orodispersible tablet is placed in the mouth where it will disperse immediately. Water or other liquid is not needed to swallow the dose. The dose must be taken as soon as the blister has been opened.

**4.3 Contraindications**

Hypersensitivity to the active substance, to any of the excipients listed in section 6.1, or to loratadine.

**4.4 Special warnings and precautions for use**

In the case of severe renal insufficiency, Aerius should be used with caution (see section 5.2).

Desloratadine should be administered with caution in patients with medical or familial history of seizures, and mainly young children (see section 4.8), being more susceptible to develop new seizures under desloratadine treatment. Healthcare providers may consider discontinuing desloratadine in patients who experience a seizure while on treatment.

This product contains 1.4 mg of phenylalanine per 2.5 mg dose of Aerius orodispersible tablet. Phenylalanine may be harmful for people with phenylketonuria.

**4.5 Interaction with other medicinal products and other forms of interaction**

No clinically relevant interactions were observed in clinical trials with desloratadine tablets in which erythromycin or ketoconazole were co-administered (see section 5.1).

Paediatric population

Interaction studies have only been performed in adults.

In a clinical pharmacology trial, Aerius tablets taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol (see section 5.1). However, cases of alcohol intolerance and intoxication have been reported during post‑marketing use. Therefore, caution is recommended if alcohol is taken concomitantly.

**4.6 Fertility, pregnancy and lactation**

Pregnancy

A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no malformative nor foeto/ neonatal toxicity of desloratadine. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of Aerius during pregnancy.

Breast-feeding

Desloratadine has been identified in breastfed newborns/infants of treated women. The effect of desloratadine on newborns/infants is unknown. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Aerius therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

Fertility

There are no data available on male and female fertility.

**4.7 Effects on ability to drive and use machines**

Aerius has no or negligible influence on the ability to drive and use machines based on clinical trials.

Patients should be informed that most people do not experience drowsiness. Nevertheless, as there is individual variation in response to all medicinal products, it is recommended that patients are advised not to engage in activities requiring mental alertness, such as driving a car or using machines, until they have established their own response to the medicinal product.

**4.8 Undesirable effects**

Summary of the safety profile

In clinical trials, desloratadine in the syrup formulation was administered to a paediatric population. The overall incidence of adverse reactions was similar between the desloratadine syrup and the placebo groups and did not differ significantly than the safety profile seen in adult patients.

In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Aerius tablets were reported in 3 % of patients in excess of those treated with placebo. The most frequent of adverse events reported in excess of placebo were fatigue (1.2 %), dry mouth (0.8 %) and headache (0.6 %).

Paediatric population

In a clinical trial with 578 adolescent patients, 12 through 17 years of age, the most common adverse event was headache; this occurred in 5.9 % of patients treated with desloratadine and 6.9 % of patients receiving placebo.

Tabulated list of adverse reactions

The frequency of the clinical trial adverse reactions reported in excess of placebo and other undesirable effects reported during the post-marketing period are listed in the following table. Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).

| **System Organ Class** | **Frequency** | **Adverse reactions seen with Aerius** |
| --- | --- | --- |
| **Metabolism and nutrition disorders** | Not known | Increased appetite |
| **Psychiatric disorders** | Very rare  Not known | Hallucinations  Abnormal behaviour, aggression |
| **Nervous system disorders** | Common  Very rare | Headache  Dizziness, somnolence, insomnia, psychomotor hyperactivity, seizures |
| **Cardiac disorders** | Very rare  Not known | Tachycardia, palpitations  QT prolongation |
| **Gastrointestinal disorders** | Common  Very rare | Dry mouth  Abdominal pain, nausea, vomiting, dyspepsia, diarrhoea |
| **Hepatobiliary disorders** | Very rare  Not known | Elevations of liver enzymes, increased bilirubin, hepatitis  Jaundice |
| **Skin and subcutaneous tissue disorders** | Not known | Photosensitivity |
| **Musculoskeletal and connective tissue disorders** | Very rare | Myalgia |
| **General disorders and administration site conditions** | Common  Very rare  Not known | Fatigue  Hypersensitivity reactions (such as anaphylaxis, angioedema, dyspnoea, pruritus, rash, and urticaria)  Asthenia |
| **Investigations** | Not known | Weight increased |

Paediatric population

Other undesirable effects reported during the post‑marketing period in paediatric patients with an unknown frequency included QT prolongation, arrhythmia, bradycardia, abnormal behaviour, and aggression.

A retrospective observational safety study indicated an increased incidence of new-onset seizure in patients 0 to 19 years of age when receiving desloratadine compared with periods not receiving desloratadine. Among children 0-4 years old, the adjusted absolute increase was 37.5 (95% Confidence Interval (CI) 10.5-64.5) per 100,000 person years (PY) with a background rate of new onset seizure of 80.3 per 100,000 PY. Among patients 5-19 years of age, the adjusted absolute increase was 11.3 (95% CI 2.3-20.2) per 100,000 PY with a background rate of 36.4 per 100,000 PY. (See section 4.4.)

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc).

**4.9 Overdose**

The adverse event profile associated with overdosage, as seen during post‑marketing use, is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher.

Treatment

In the event of overdose, consider standard measures to remove unabsorbed active substance. Symptomatic and supportive treatment is recommended.

Desloratadine is not eliminated by haemodialysis; it is not known if it is eliminated by peritoneal dialysis.

Symptoms

Based on a multiple dose clinical trial, in which up to 45 mg of desloratadine was administered (nine times the clinical dose), no clinically relevant effects were observed.

Paediatric population

The adverse event profile associated with overdosage, as seen during post‑marketing use, is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: antihistamines – H1 antagonist, ATC code: R06A X27

Mechanism of action

Desloratadine is a non-sedating, long-acting histamine antagonist with selective peripheral H1-receptor antagonist activity. After oral administration, desloratadine selectively blocks peripheral histamine H1-receptors because the substance is excluded from entry to the central nervous system.

Desloratadine has demonstrated antiallergic properties from *in vitro* studies.These include inhibiting the release of proinflammatory cytokines such as IL-4, IL-6, IL-8, and IL-13 from human mast cells/basophils, as well as inhibition of the expression of the adhesion molecule P-selectin on endothelial cells. The clinical relevance of these observations remains to be confirmed.

Clinical efficacy and safety

In a multiple dose trial, Aerius orodispersible tablets were well tolerated.

At the recommended dose, Aerius 5 mg orodispersible tablet was found to be bioequivalent to the Aerius 5 mg conventional tablet formulation of desloratadine. Therefore, the efficacy of Aerius orodispersible tablet is expected to be the same as with the Aerius tablet formulation.

In a multiple dose clinical trial, in which up to 20 mg of desloratadine was administered daily for 14 days, no statistically or clinically relevant cardiovascular effect was observed. In a clinical pharmacology trial, in which desloratadine was administered at a dose of 45 mg daily (nine times the clinical dose) for ten days, no prolongation of QTc interval was seen.

No clinically relevant changes in desloratadine plasma concentrations were observed in multiple-dose, ketoconazole and erythromycin interaction trials.

Desloratadine does not readily penetrate the central nervous system. In clinical trials, at the recommended dose of 5 mg daily, there was no excess incidence of somnolence as compared to placebo. Aerius tablets given at a single daily dose of 7.5 mg did not affect psychomotor performance in clinical trials. In a single dose study performed in adults, desloratadine 5 mg did not affect standard measures of flight performance including exacerbation of subjective sleepiness or tasks related to flying.

In clinical pharmacology trials, co-administration with alcohol did not increase the alcohol-induced impairment in performance or increase in sleepiness. No significant differences were found in the psychomotor test results between desloratadine and placebo groups, whether administered alone or with alcohol.

In patients with allergic rhinitis, Aerius tablets were effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate. Aerius tablets effectively controlled symptoms for 24 hours.

Paediatric population

The efficacy of Aerius tablets has not been clearly demonstrated in trials with adolescent patients 12 through 17 years of age.

In addition to the established classifications of seasonal and perennial, allergic rhinitis can alternatively be classified as intermittent allergic rhinitis and persistent allergic rhinitis according to the duration of symptoms. Intermittent allergic rhinitis is defined as the presence of symptoms for less than 4 days per week or for less than 4 weeks. Persistent allergic rhinitis is defined as the presence of symptoms for 4 days or more per week and for more than 4 weeks.

Aerius was effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire. The greatest amelioration was seen in the domains of practical problems and daily activities limited by symptoms.

Chronic idiopathic urticaria was studied as a clinical model for urticarial conditions, since the underlying pathophysiology is similar, regardless of etiology, and because chronic patients can be more easily recruited prospectively. Since histamine release is a causal factor in all urticarial diseases, desloratadine is expected to be effective in providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathic urticaria, as advised in clinical guidelines.

In two placebo-controlled six week trials in patients with chronic idiopathic urticaria, Aerius was effective in relieving pruritus and decreasing the size and number of hives by the end of the first dosing interval. In each trial, the effects were sustained over the 24 hour dosing interval. As with other antihistamine trials in chronic idiopathic urticaria, the minority of patients who were identified as non-responsive to antihistamines was excluded. An improvement in pruritus of more than 50 % was observed in 55 % of patients treated with desloratadine compared with 19 % of patients treated with placebo. Treatment with Aerius also significantly reduced interference with sleep and daytime function, as measured by a four-point scale used to assess these variables.

**5.2 Pharmacokinetic properties**

Absorption

Desloratadine plasma concentrations can be detected within 30 minutes of administration. Desloratadine is well absorbed with maximum concentration achieved after approximately 3 hours; the terminal phase half-life is approximately 27 hours. The degree of accumulation of desloratadine was consistent with its half-life (approximately 27 hours) and a once daily dosing frequency. The bioavailability of desloratadine was dose proportional over the range of 5 mg to 20 mg.

In a series of pharmacokinetic and clinical trials, 6 % of the subjects reached a higher concentration of desloratadine. The prevalence of this poor metaboliser phenotype was comparable for adult (6 %) and paediatric subjects 2- to 11-year old (6 %), and greater among Blacks (18 % adult, 16 % paediatric) than Caucasians (2 % adult, 3 % paediatric) in both populations however the safety profile of these subjects was not different from that of the general population.

In a multiple-dose pharmacokinetic study conducted with the tablet formulation in healthy adult subjects, four subjects were found to be poor metabolisers of desloratadine. These subjects had a Cmax concentration about 3-fold higher at approximately 7 hours with a terminal phase half-life of approximately 89 hours.

Distribution

Desloratadine is moderately bound (83 % - 87 %) to plasma proteins. There is no evidence of clinically relevant medicine accumulation following once daily dosing of desloratadine (5 mg to 20 mg) for 14 days.

Biotransformation

The enzyme responsible for the metabolism of desloratadine has not been identified yet, and therefore, some interactions with other medicinal products cannot be fully excluded. Desloratadine does not inhibit CYP3A4 *in vivo,* and *in vitro* studies have shown that the medicinal product does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein.

In single-dose crossover studies of Aerius 5 mg orodispersible tablets with Aerius 5 mg conventional tablets, the formulations were bioequivalent. Aerius 2.5 mg tablets has not been evaluated in paediatric patients however in conjunction with the dose finding studies in paediatrics, the pharmacokinetics data for Aerius orodispersible tablets supports the use of the 2.5 mg dose in paediatric patients 6 to 11 years of age.

Elimination

The presence of food prolongs Tmax for desloratadine from 2.5 to 4 hours and Tmax for 3-OH-desloratadine from 4 to 6 hours. In a separate study, grapefruit juice had no effect on the disposition of desloratadine. Water had no effect on the bioavailability of Aerius orodispersible tablets.

Renally impaired patients

The pharmacokinetics of desloratadine in patients with chronic renal insufficiency (CRI) was compared with that of healthy subjects in one single‑dose study and one multiple dose study. In the single‑dose study, the exposure to desloratadine was approximately 2 and 2.5‑fold greater in subjects with mild to moderate and severe CRI, respectively, than in healthy subjects. In the multiple‑dose study, steady state was reached after Day 11, and compared to healthy subjects the exposure to desloratadine was ~1.5‑fold greater in subjects with mild to moderate CRI and ~2.5‑fold greater in subjects with severe CRI. In both studies, changes in exposure (AUC and Cmax) of desloratadine and 3‑hydroxydesloratadine were not clinically relevant.

**5.3 Preclinical safety data**

Desloratadine is the primary active metabolite of loratadine. Non-clinical studies conducted with desloratadine and loratadine demonstrated that there are no qualitative or quantitative differences in the toxicity profile of desloratadine and loratadine at comparable levels of exposure to desloratadine.

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. The collective analysis of preclinical and clinical irritation studies for the orodispersible tablet indicate that this formulation in unlikely to pose risk for local irritation with clinical use. The lack of carcinogenic potential was demonstrated in studies conducted with desloratadine and loratadine.

**6. PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

microcrystalline cellulose

pregelatinized starch

sodium starch glycolate

magnesium stearate

butylated methacrylate copolymer

crospovidone

sodium hydrogen carbonate

citric acid

colloidal silicon dioxide

ferric oxide

mannitol

aspartame (E951)

flavour Tutti-Frutti

**6.2 Incompatibilities**

Not applicable.

**6.3 Shelf life**

2 years

**6.4 Special precautions for storage**

Store in the original package.

**6.5 Nature and contents of container**

Aerius orodispersible tablets are supplied in unit dose blisters comprised of laminate blister film with foil lidding.

The blister materials consist of a four layer aluminum foil laminate cold form blister film and a paper backed laminated aluminum foil lidding film.

The cold form blister film is composed of polyvinyl chloride (PVC) film adhesively laminated to an oriented polyamide (OPA) film, adhesively laminated to aluminum foil, adhesively laminated to polyvinyl chloride (PVC) film.

Packs of 5, 6, 10, 12, 15, 18, 20, 30, 50, 60, 90 and 100 orodispersible tablets.

Not all pack sizes may be marketed.

**6.6 Special precautions for disposal**

No special requirements

**7. MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.

Waarderweg 39

2031 BN Haarlem

The Netherlands

**8. MARKETING AUTHORISATION NUMBERS**

EU/1/00/160/037-048

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 15 January 2001

Date of latest renewal: 15 January 2006

**10. DATE OF REVISION OF THE TEXT**

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.

**1. NAME OF THE MEDICINAL PRODUCT**

Aerius 5 mg orodispersible tablets

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each orodispersible tablet contains 5 mg desloratadine.

Excipient(s) with known effect:

This medicine contains mannitol and aspartame (E951).

For the full list of excipients, see section 6.1.

**3. PHARMACEUTICAL FORM**

Orodispersible tablet

Light-red, flat-faced, round, speckled tablets, one side branded with “A”

**4. CLINICAL PARTICULARS**

**4.1 Therapeutic indications**

Aerius is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with:

* allergic rhinitis (see section 5.1)
* urticaria (see section 5.1)

**4.2 Posology and method of administration**

Posology

*Adults and adolescents (12 years of age and over)*

The recommended dose of Aerius is one 5 mg orodispersible tablet placed in the mouth once a day.

Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient’s disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance. In persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks), continued treatment may be proposed to the patients during the allergen exposure periods.

*Paediatric population*

The safety and efficacy of Aerius 5 mg orodispersible tablets in children below the age of 12 years have not been established.

There is limited clinical trial efficacy experience with the use of desloratadine in adolescents 12 through 17 years of age (see sections 4.8 and 5.1).

Method of administration

Oral use.

The dose can be taken with or without food.

Immediately before use, the blister must be carefully peeled open and the dose of orodispersible tablet removed without crushing it. The dose of orodispersible tablet is placed in the mouth where it will disperse immediately. Water or other liquid is not needed to swallow the dose. The dose must be taken as soon as the blister has been opened.

**4.3 Contraindications**

Hypersensitivity to the active substance, to any of the excipients listed in section 6.1, or to loratadine.

**4.4 Special warnings and precautions for use**

In the case of severe renal insufficiency, Aerius should be used with caution (see section 5.2).

Desloratadine should be administered with caution in patients with medical or familial history of seizures, and mainly young children (see section 4.8), being more susceptible to develop new seizures under desloratadine treatment. Healthcare providers may consider discontinuing desloratadine in patients who experience a seizure while on treatment.

This product contains 2.9 mg of phenylalanine per 5 mg dose of Aerius orodispersible tablet. Phenylalanine may be harmful for people with phenylketonuria.

**4.5 Interaction with other medicinal products and other forms of interaction**

No clinically relevant interactions were observed in clinical trials with desloratadine tablets in which erythromycin or ketoconazole were co-administered (see section 5.1).

Paediatric population

Interaction studies have only been performed in adults.

In a clinical pharmacology trial, Aerius tablets taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol (see section 5.1). However, cases of alcohol intolerance and intoxication have been reported during post‑marketing use. Therefore, caution is recommended if alcohol is taken concomitantly.

**4.6 Fertility, pregnancy and lactation**

Pregnancy

A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no malformative nor foeto/ neonatal toxicity of desloratadine. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of Aerius during pregnancy.

Breast-feeding

Desloratadine has been identified in breastfed newborns/infants of treated women. The effect of desloratadine on newborns/infants is unknown. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Aerius therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

Fertility

There are no data available on male and female fertility.

**4.7 Effects on ability to drive and use machines**

Aerius has no or negligible influence on the ability to drive and use machines based on clinical trials. Patients should be informed that most people do not experience drowsiness. Nevertheless, as there is individual variation in response to all medicinal products, it is recommended that patients are advised not to engage in activities requiring mental alertness, such as driving a car or using machines, until they have established their own response to the medicinal product.

**4.8 Undesirable effects**

Summary of the safety profile

In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Aerius tablets were reported in 3 % of patients in excess of those treated with placebo. The most frequent of adverse reactions reported in excess of placebo were fatigue (1.2 %), dry mouth (0.8 %) and headache (0.6 %).

Paediatric population

In a clinical trial with 578 adolescent patients, 12 through 17 years of age, the most common adverse event was headache; this occurred in 5.9 % of patients treated with desloratadine and 6.9 % of patients receiving placebo.

Tabulated list of adverse reactions

The frequency of the clinical trial adverse reactions reported in excess of placebo and other undesirable effects reported during the post-marketing period are listed in the following table. Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).

| **System Organ Class** | **Frequency** | **Adverse reactions seen with Aerius** |
| --- | --- | --- |
| **Metabolism and nutrition disorders** | Not known | Increased appetite |
| **Psychiatric disorders** | Very rare  Not known | Hallucinations  Abnormal behaviour, aggression |
| **Nervous system disorders** | Common  Very rare | Headache  Dizziness, somnolence, insomnia, psychomotor hyperactivity, seizures |
| **Cardiac disorders** | Very rare  Not known | Tachycardia, palpitations  QT prolongation |
| **Gastrointestinal disorders** | Common  Very rare | Dry mouth  Abdominal pain, nausea, vomiting, dyspepsia, diarrhoea |
| **Hepatobiliary disorders** | Very rare  Not known | Elevations of liver enzymes, increased bilirubin, hepatitis  Jaundice |
| **Skin and subcutaneous tissue disorders** | Not known | Photosensitivity |
| **Musculoskeletal and connective tissue disorders** | Very rare | Myalgia |
| **General disorders and administration site conditions** | Common  Very rare  Not known | Fatigue  Hypersensitivity reactions (such as anaphylaxis, angioedema, dyspnoea, pruritus, rash, and urticaria)  Asthenia |
| **Investigations** | Not known | Weight increased |

Paediatric population

Other undesirable effects reported during the post‑marketing period in paediatric patients with an unknown frequency included QT prolongation, arrhythmia, bradycardia, abnormal behaviour, and aggression.

A retrospective observational safety study indicated an increased incidence of new-onset seizure in patients 0 to 19 years of age when receiving desloratadine compared with periods not receiving desloratadine. Among children 0-4 years old, the adjusted absolute increase was 37.5 (95% Confidence Interval (CI) 10.5-64.5) per 100,000 person years (PY) with a background rate of new onset seizure of 80.3 per 100,000 PY. Among patients 5-19 years of age, the adjusted absolute increase was 11.3 (95% CI 2.3-20.2) per 100,000 PY with a background rate of 36.4 per 100,000 PY. (See section 4.4.)

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc).

**4.9 Overdose**

The adverse event profile associated with overdosage, as seen during post‑marketing use, is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher.

Treatment

In the event of overdose, consider standard measures to remove unabsorbed active substance. Symptomatic and supportive treatment is recommended.

Desloratadine is not eliminated by haemodialysis; it is not known if it is eliminated by peritoneal dialysis.

Symptoms

Based on a multiple dose clinical trial, in which up to 45 mg of desloratadine was administered (nine times the clinical dose), no clinically relevant effects were observed.

Paediatric population

The adverse event profile associated with overdosage, as seen during post‑marketing use, is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: antihistamines – H1 antagonist, ATC code: R06A X27

Mechanism of action

Desloratadine is a non-sedating, long-acting histamine antagonist with selective peripheral H1-receptor antagonist activity. After oral administration, desloratadine selectively blocks peripheral histamine H1-receptors because the substance is excluded from entry to the central nervous system.

Desloratadine has demonstrated antiallergic properties from *in vitro* studies.These include inhibiting the release of proinflammatory cytokines such as IL-4, IL-6, IL-8, and IL-13 from human mast cells/basophils, as well as inhibition of the expression of the adhesion molecule P-selectin on endothelial cells. The clinical relevance of these observations remains to be confirmed.

Clinical efficacy and safety

In a multiple dose trial, Aerius orodispersible tablets were well tolerated.

At the recommended dose, Aerius 5 mg orodispersible tablet was found to be bioequivalent to the Aerius 5 mg conventional tablet formulation of desloratadine. Therefore, the efficacy of Aerius orodispersible tablet is expected to be the same as with the Aerius tablet formulation.

In a multiple-dose clinical trial, in which up to 20 mg of desloratadine was administered daily for 14 days, no statistically or clinically relevant cardiovascular effect was observed. In a clinical pharmacology trial, in which desloratadine was administered at a dose of 45 mg daily (nine times the clinical dose) for ten days, no prolongation of QTc interval was seen.

No clinically relevant changes in desloratadine plasma concentrations were observed in multiple-dose, ketoconazole and erythromycin interaction trials.

Desloratadine does not readily penetrate the central nervous system. In clinical trials, at the recommended dose of 5 mg daily, there was no excess incidence of somnolence as compared to placebo. Aerius tablets given at a single daily dose of 7.5 mg did not affect psychomotor performance in clinical trials. In a single dose study performed in adults, desloratadine 5 mg did not affect standard measures of flight performance including exacerbation of subjective sleepiness or tasks related to flying.

In clinical pharmacology trials, co-administration with alcohol did not increase the alcohol-induced impairment in performance or increase in sleepiness. No significant differences were found in the psychomotor test results between desloratadine and placebo groups, whether administered alone or with alcohol.

In patients with allergic rhinitis, Aerius tablets were effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate. Aerius tablets effectively controlled symptoms for 24 hours.

Paediatric population

The efficacy of Aerius tablets has not been clearly demonstrated in trials with adolescent patients 12 through 17 years of age.

In addition to the established classifications of seasonal and perennial, allergic rhinitis can alternatively be classified as intermittent allergic rhinitis and persistent allergic rhinitis according to the duration of symptoms. Intermittent allergic rhinitis is defined as the presence of symptoms for less than 4 days per week or for less than 4 weeks. Persistent allergic rhinitis is defined as the presence of symptoms for 4 days or more per week and for more than 4 weeks.

Aerius was effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire. The greatest amelioration was seen in the domains of practical problems and daily activities limited by symptoms.

Chronic idiopathic urticaria was studied as a clinical model for urticarial conditions, since the underlying pathophysiology is similar, regardless of etiology, and because chronic patients can be more easily recruited prospectively. Since histamine release is a causal factor in all urticarial diseases, desloratadine is expected to be effective in providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathic urticaria, as advised in clinical guidelines.

In two placebo-controlled six week trials in patients with chronic idiopathic urticaria, Aerius was effective in relieving pruritus and decreasing the size and number of hives by the end of the first dosing interval. In each trial, the effects were sustained over the 24 hour dosing interval. As with other antihistamine trials in chronic idiopathic urticaria, the minority of patients who were identified as non-responsive to antihistamines was excluded. An improvement in pruritus of more than 50 % was observed in 55 % of patients treated with desloratadine compared with 19 % of patients treated with placebo. Treatment with Aerius also significantly reduced interference with sleep and daytime function, as measured by a four-point scale used to assess these variables.

**5.2 Pharmacokinetic properties**

Absorption

Desloratadine plasma concentrations can be detected within 30 minutes of administration. Desloratadine is well absorbed with maximum concentration achieved after approximately 3 hours; the terminal phase half-life is approximately 27 hours. The degree of accumulation of desloratadine was consistent with its half-life (approximately 27 hours) and a once daily dosing frequency. The bioavailability of desloratadine was dose proportional over the range of 5 mg to 20 mg.

In a series of pharmacokinetic and clinical trials, 6 % of the subjects reached a higher concentration of desloratadine. The prevalence of this poor metaboliser phenotype was greater among Black adults than Caucasian adults (18 % vs. 2 %) however the safety profile of these subjects was not different from that of the general population.

In a multiple-dose pharmacokinetic study conducted with the tablet formulation in healthy adult subjects, four subjects were found to be poor metabolisers of desloratadine. These subjects had a Cmax concentration about 3-fold higher at approximately 7 hours with a terminal phase half-life of approximately 89 hours.

Distribution

Desloratadine is moderately bound (83 % - 87 %) to plasma proteins. There is no evidence of clinically relevant medicine accumulation following once daily dosing of desloratadine (5 mg to 20 mg) for 14 days.

Biotransformation

The enzyme responsible for the metabolism of desloratadine has not been identified yet, and therefore, some interactions with other medicinal products cannot be fully excluded. Desloratadine does not inhibit CYP3A4 *in vivo,* and *in vitro* studies have shown that the medicinal product does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein.

In single-dose crossover studies of Aerius 5 mg orodispersible tablets with Aerius 5 mg conventional tablets, the formulations were bioequivalent.

Elimination

The presence of food prolongs Tmax for desloratadine from 2.5 to 4 hours and Tmax for 3-OH-desloratadine from 4 to 6 hours. In a separate study, grapefruit juice had no effect on the disposition of desloratadine. Water had no effect on the bioavailability of Aerius orodispersible tablets.

Renally impaired patients

The pharmacokinetics of desloratadine in patients with chronic renal insufficiency (CRI) was compared with that of healthy subjects in one single‑dose study and one multiple dose study. In the single‑dose study, the exposure to desloratadine was approximately 2 and 2.5‑fold greater in subjects with mild to moderate and severe CRI, respectively, than in healthy subjects. In the multiple‑dose study, steady state was reached after Day 11, and compared to healthy subjects the exposure to desloratadine was ~1.5‑fold greater in subjects with mild to moderate CRI and ~2.5‑fold greater in subjects with severe CRI. In both studies, changes in exposure (AUC and Cmax) of desloratadine and 3‑hydroxydesloratadine were not clinically relevant.

**5.3 Preclinical safety data**

Desloratadine is the primary active metabolite of loratadine. Non-clinical studies conducted with desloratadine and loratadine demonstrated that there are no qualitative or quantitative differences in the toxicity profile of desloratadine and loratadine at comparable levels of exposure to desloratadine.

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. The collective analysis of preclinical and clinical irritation studies for the orodispersible tablet indicate that this formulation is unlikely to pose risk for local irritation with clinical use. The lack of carcinogenic potential was demonstrated in studies conducted with desloratadine and loratadine.

**6. PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

microcrystalline cellulose

pregelatinized starch

sodium starch glycolate

magnesium stearate

butylated methacrylate copolymer

crospovidone

sodium hydrogen carbonate

citric acid

colloidal silicon dioxide

ferric oxide

mannitol

aspartame (E951)

flavour Tutti-Frutti

**6.2 Incompatibilities**

Not applicable.

**6.3 Shelf life**

2 years

**6.4 Special precautions for storage**

Store in the original package.

**6.5 Nature and contents of container**

Aerius orodispersible tablets are supplied in unit dose blisters comprised of laminate blister film with foil lidding.

The blister materials consist of a four layer aluminum foil laminate cold form blister film and a paper backed laminated aluminum foil lidding film.

The cold form blister film is composed of polyvinyl chloride (PVC) film adhesively laminated to an oriented polyamide (OPA) film, adhesively laminated to aluminum foil, adhesively laminated to polyvinyl chloride (PVC) film.

Packs of 5, 6, 10, 12, 15, 18, 20, 30, 50, 60, 90 and 100 orodispersible tablets.

Not all pack sizes may be marketed.

**6.6 Special precautions for disposal**

No special requirements

**7. MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.

Waarderweg 39

2031 BN Haarlem

The Netherlands

**8. MARKETING AUTHORISATION NUMBERS**

EU/1/00/160/049-060

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 15 January 2001

Date of latest renewal: 15 January 2006

**10. DATE OF REVISION OF THE TEXT**

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.

**1. NAME OF THE MEDICINAL PRODUCT**

Aerius 0.5 mg/ml oral solution

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml of oral solution contains 0.5 mg desloratadine.

Excipient(s) with known effect:

This medicinal product contains 150 mg/ml of sorbitol

For the full list of excipients, see section 6.1.

**3. PHARMACEUTICAL FORM**

Oral solution

**4. CLINICAL PARTICULARS**

**4.1 Therapeutic indications**

Aerius is indicated in adults, adolescents and children over the age of 1 year for the relief of symptoms associated with:

* allergic rhinitis (see section 5.1)
* urticaria (see section 5.1)

**4.2 Posology and method of administration**

Posology

*Adults and adolescents (12* *years of age and over)*

The recommended dose of Aerius is 10 ml (5 mg) oral solution once a day.

*Paediatric population*

The prescriber should be aware that most cases of rhinitis below 2 years of age are of infectious origin (see section 4.4) and there are no data supporting the treatment of infectious rhinitis with Aerius.

Children 1 through 5 years of age: 2.5 ml (1.25 mg) Aerius oral solution once a day.

Children 6 through 11 years of age: 5 ml (2.5 mg) Aerius oral solution once a day.

The safety and efficacy of Aerius 0.5 mg/ml oral solution in children below the age of 1 year have not been established.

There is limited clinical trial efficacy experience with the use of desloratadine in children 1 through 11 years of age and adolescents 12 through 17 years of age (see sections 4.8 and 5.1).

Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient’s disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance.

In persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks), continued treatment may be proposed to the patients during the allergen exposure periods.

Method of administration

Oral use.

The dose can be taken with or without food.

**4.3 Contraindications**

Hypersensitivity to the active substance, to any of the excipients listed in section 6.1, or to loratadine.

**4.4 Special warnings and precautions for use**

Desloratadine should be administered with caution in patients with medical or familial history of seizures, and mainly young children (see section 4.8), being more susceptible to develop new seizures under desloratadine treatment. Healthcare providers may consider discontinuing desloratadine in patients who experience a seizure while on treatment.

Paediatric population

In children below 2 years of age, the diagnosis of allergic rhinitis is particularly difficult to distinguish from other forms of rhinitis. The absence of upper respiratory tract infection or structural abnormalities, as well as patient history, physical examinations, and appropriate laboratory and skin tests should be considered.

Approximately 6 % of adults and children 2- to 11-year old are phenotypic poor metabolisers of desloratadine and exhibit a higher exposure (see section 5.2). The safety of desloratadine in children 2- to 11-years of age who are poor metabolisers is the same as in children who are normal metabolisers. The effects of desloratadine in poor metabolisers < 2 years of age have not been studied.

In the case of severe renal insufficiency, Aerius should be used with caution (see section 5.2).

This medicinal product contains sorbitol; thus, patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

**4.5 Interaction with other medicinal products and other forms of interaction**

No clinically relevant interactions were observed in clinical trials with desloratadine tablets in which erythromycin or ketoconazole were co-administered (see section 5.1).

Paediatric population

Interaction studies have only been performed in adults.

In a clinical pharmacology trial, Aerius tablets taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol (see section 5.1). However, cases of alcohol intolerance and intoxication have been reported during post‑marketing use. Therefore, caution is recommended if alcohol is taken concomitantly.

**4.6 Fertility, pregnancy and lactation**

Pregnancy

A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no malformative nor foeto/ neonatal toxicity of desloratadine. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of Aerius during pregnancy.

Breast-feeding

Desloratadine has been identified in breastfed newborns/infants of treated women. The effect of desloratadine on newborns/infants is unknown. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Aerius therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

Fertility

There are no data available on male and female fertility.

**4.7 Effects on ability to drive and use machines**

Aerius has no or negligible influence on the ability to drive and use machines based on clinical trials. Patients should be informed that most people do not experience drowsiness. Nevertheless, as there is individual variation in response to all medicinal products, it is recommended that patients are advised not to engage in activities requiring mental alertness, such as driving a car or using machines, until they have established their own response to the medicinal product.

**4.8 Undesirable effects**

Summary of the safety profile

Paediatric population

In clinical trials in a paediatric population, the desloratadine syrup formulation was administered to a total of 246 children aged 6 months through 11 years. The overall incidence of adverse events in children 2 through 11 years of age was similar for the desloratadine and the placebo groups. In infants and toddlers aged 6 to 23 months, the most frequent adverse reactions reported in excess of placebo were diarrhoea (3.7 %), fever (2.3 %) and insomnia (2.3 %). In an additional study, no adverse events were seen in subjects between 6 and 11 years of age following a single 2.5 mg dose of desloratadine oral solution.

In a clinical trial with 578 adolescent patients, 12 through 17 years of age, the most common adverse event was headache; this occurred in 5.9 % of patients treated with desloratadine and 6.9 % of patients receiving placebo.

Adults and adolescents

At the recommended dose, in clinical trials involving adults and adolescents in a range of indications including allergic rhinitis and chronic idiopathic urticaria, undesirable effects with Aerius were reported in 3 % of patients in excess of those treated with placebo. The most frequent of adverse events reported in excess of placebo were fatigue (1.2 %), dry mouth (0.8 %) and headache (0.6 %).

Tabulated list of adverse reactions

The frequency of the clinical trial adverse reactions reported in excess of placebo and other undesirable effects reported during the post-marketing period are listed in the following table. Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).

| **System Organ Class** | **Frequency** | **Adverse reactions seen with Aerius** |
| --- | --- | --- |
| **Metabolism and nutrition disorders** | Not known | Increased appetite |
| **Psychiatric disorders** | Very rare  Not known | Hallucinations  Abnormal behaviour, aggression |
| **Nervous system disorders** | Common  Common (children less than 2 years)  Very rare | Headache  Insomnia  Dizziness, somnolence, insomnia, psychomotor hyperactivity, seizures |
| **Cardiac disorders** | Very rare  Not known | Tachycardia, palpitations  QT prolongation |
| **Gastrointestinal disorders** | Common  Common (children less than 2 years)  Very rare | Dry mouth  Diarrhoea  Abdominal pain, nausea, vomiting, dyspepsia, diarrhoea |
| **Hepatobiliary disorders** | Very rare  Not known | Elevations of liver enzymes, increased bilirubin, hepatitis  Jaundice |
| **Skin and subcutaneous tissue disorders** | Not known | Photosensitivity |
| **Musculoskeletal and connective tissue disorders** | Very rare | Myalgia |
| **General disorders and administration site conditions** | Common  Common (children less than 2 years)  Very rare  Not known | Fatigue  Fever  Hypersensitivity reactions (such as anaphylaxis, angioedema, dyspnoea, pruritus, rash, and urticaria)  Asthenia |
| **Investigations** | Not known | Weight increased |

Paediatric population

Other undesirable effects reported during the post‑marketing period in paediatric patients with an unknown frequency included QT prolongation, arrhythmia, bradycardia, abnormal behaviour, and aggression.

A retrospective observational safety study indicated an increased incidence of new-onset seizure in patients 0 to 19 years of age when receiving desloratadine compared with periods not receiving desloratadine. Among children 0-4 years old, the adjusted absolute increase was 37.5 (95% Confidence Interval (CI) 10.5-64.5) per 100,000 person years (PY) with a background rate of new onset seizure of 80.3 per 100,000 PY. Among patients 5-19 years of age, the adjusted absolute increase was 11.3 (95% CI 2.3-20.2) per 100,000 PY with a background rate of 36.4 per 100,000 PY. (See section 4.4.)

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc).

**4.9 Overdose**

The adverse event profile associated with overdosage, as seen during post‑marketing use, is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher.

Treatment

In the event of overdose, consider standard measures to remove unabsorbed active substance. Symptomatic and supportive treatment is recommended.

Desloratadine is not eliminated by haemodialysis; it is not known if it is eliminated by peritoneal dialysis.

Symptoms

Based on a multiple dose clinical trial in adults and adolescents, in which up to 45 mg of desloratadine was administered (nine times the clinical dose), no clinically relevant effects were observed.

Paediatric population

The adverse event profile associated with overdosage, as seen during post‑marketing use, is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: antihistamines – H1 antagonist, ATC code: R06A X27

Mechanism of action

Desloratadine is a non-sedating, long-acting histamine antagonist with selective peripheral H1-receptor antagonist activity. After oral administration, desloratadine selectively blocks peripheral histamine H1-receptors because the substance is excluded from entry to the central nervous system.

Desloratadine has demonstrated antiallergic properties from *in* *vitro* studies. These include inhibiting the release of proinflammatory cytokines such as IL-4, IL-6, IL-8, and IL-13 from human mast cells/basophils, as well as inhibition of the expression of the adhesion molecule P-selectin on endothelial cells. The clinical relevance of these observations remains to be confirmed.

Clinical efficacy and safety

Paediatric population

Efficacy of Aerius oral solution has not been investigated in separate paediatric trials. However, the safety of desloratadine syrup formulation, which contains the same concentration of desloratadine as Aerius oral solution, was demonstrated in three paediatric trials. Children, 1-11 years of age, who were candidates for antihistamine therapy received a daily desloratadine dose of 1.25 mg (1 through 5 years of age) or 2.5 mg (6 through 11 years of age). Treatment was well tolerated as documented by clinical laboratory tests, vital signs, and ECG interval data, including QTc. When given at the recommended doses, the plasma concentrations of desloratadine (see section 5.2) were comparable in the paediatric and adult populations. Thus, since the course of allergic rhinitis/chronic idiopathic urticaria and the profile of desloratadine are similar in adults and paediatric patients, desloratadine efficacy data in adults can be extrapolated to the paediatric population.

Efficacy of Aerius syrup has not been investigated in paediatric trials in children less than 12 years of age.

Adults and adolescents

In a multiple dose clinical trial, in adults and adolescents, in which up to 20 mg of desloratadine was administered daily for 14 days, no statistically or clinically relevant cardiovascular effect was observed. In a clinical pharmacology trial, in adults and adolescents, in which desloratadine was administered to adults at a dose of 45 mg daily (nine times the clinical dose) for ten days, no prolongation of QTc interval was seen.

Desloratadine does not readily penetrate the central nervous system. In controlled clinical trials, at the recommended dose of 5 mg daily for adults and adolescents, there was no excess incidence of somnolence as compared to placebo. Aerius tablets given at a single daily dose of 7.5 mg to adults and adolescents did not affect psychomotor performance in clinical trials. In a single dose study performed in adults, desloratadine 5 mg did not affect standard measures of flight performance including exacerbation of subjective sleepiness or tasks related to flying.

In clinical pharmacology trials in adults, co-administration with alcohol did not increase the alcohol-induced impairment in performance or increase in sleepiness. No significant differences were found in the psychomotor test results between desloratadine and placebo groups, whether administered alone or with alcohol.

No clinically relevant changes in desloratadine plasma concentrations were observed in multiple-dose ketoconazole and erythromycin interaction trials.

In adult and adolescent patients with allergic rhinitis, Aerius tablets were effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate. Aerius effectively controlled symptoms for 24 hours. The efficacy of Aerius tablets has not been clearly demonstrated in trials with adolescent patients 12 through 17 years of age.

In addition to the established classifications of seasonal and perennial, allergic rhinitis can alternatively be classified as intermittent allergic rhinitis and persistent allergic rhinitis according to the duration of symptoms. Intermittent allergic rhinitis is defined as the presence of symptoms for less than 4 days per week or for less than 4 weeks. Persistent allergic rhinitis is defined as the presence of symptoms for 4 days or more per week and for more than 4 weeks.

Aerius tablets were effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire. The greatest amelioration was seen in the domains of practical problems and daily activities limited by symptoms.

Chronic idiopathic urticaria was studied as a clinical model for urticarial conditions, since the underlying pathophysiology is similar, regardless of etiology, and because chronic patients can be more easily recruited prospectively. Since histamine release is a causal factor in all urticarial diseases, desloratadine is expected to be effective in providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathic urticaria, as advised in clinical guidelines.

In two placebo-controlled six week trials in patients with chronic idiopathic urticaria, Aerius was effective in relieving pruritus and decreasing the size and number of hives by the end of the first dosing interval. In each trial, the effects were sustained over the 24 hour dosing interval. As with other antihistamine trials in chronic idiopathic urticaria, the minority of patients who were identified as non-responsive to antihistamines was excluded. An improvement in pruritus of more than 50 % was observed in 55 % of patients treated with desloratadine compared with 19 % of patients treated with placebo. Treatment with Aerius also significantly reduced interference with sleep and daytime function, as measured by a four-point scale used to assess these variables.

**5.2 Pharmacokinetic properties**

Absorption

Desloratadine plasma concentrations can be detected within 30 minutes of desloratadine administration in adults and adolescents. Desloratadine is well absorbed with maximum concentration achieved after approximately 3 hours; the terminal phase half-life is approximately 27 hours. The degree of accumulation of desloratadine was consistent with its half-life (approximately 27 hours) and a once daily dosing frequency. The bioavailability of desloratadine was dose proportional over the range of 5 mg to 20 mg.

In a series of pharmacokinetic and clinical trials, 6 % of the subjects reached a higher concentration of desloratadine. The prevalence of this poor metaboliser phenotype was comparable for adult (6 %) and paediatric subjects 2- to 11-year old (6 %), and greater among Blacks (18 % adult, 16 % paediatric) than Caucasians (2 % adult, 3 % paediatric) in both populations.

In a multiple-dose pharmacokinetic study conducted with the tablet formulation in healthy adult subjects, four subjects were found to be poor metabolisers of desloratadine. These subjects had a Cmax concentration about 3-fold higher at approximately 7 hours with a terminal phase half-life of approximately 89 hours.

Similar pharmacokinetic parameters were observed in a multiple-dose pharmacokinetic study conducted with the syrup formulation in paediatric poor metaboliser subjects 2- to 11-year old diagnosed with allergic rhinitis. The exposure (AUC) to desloratadine was about 6-fold higher and the Cmax was about 3 to 4 fold higher at 3-6 hours with a terminal half-life of approximately 120 hours. Exposure was the same in adult and paediatric poor metabolisers when treated with age-appropriate doses. The overall safety profile of these subjects was not different from that of the general population. The effects of desloratadine in poor metabolizers < 2 years of age have not been studied.

In separate single dose studies, at the recommended doses, paediatric patients had comparable AUC and Cmax values of desloratadine to those in adults who received a 5 mg dose of desloratadine syrup.

Distribution

Desloratadine is moderately bound (83 % - 87 %) to plasma proteins. There is no evidence of clinically relevant active substance accumulation following once daily adult and adolescent dosing of desloratadine (5 mg to 20 mg) for 14 days.

In a single dose, crossover study of desloratadine, the tablet and the syrup formulations were found to be bioequivalent. As Aerius oral solution contains the same concentration of desloratadine, no bioequivalence study was required and it is expected to be equivalent to the syrup and tablet.

Biotransformation

The enzyme responsible for the metabolism of desloratadine has not been identified yet, and therefore, some interactions with other medicinal products cannot be fully excluded. Desloratadine does not inhibit CYP3A4 *in vivo,* and *in vitro* studies have shown that the medicinal product does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein.

Elimination

In a single dose trial using a 7.5 mg dose of desloratadine, there was no effect of food (high-fat, high caloric breakfast) on the disposition of desloratadine. In another study, grapefruit juice had no effect on the disposition of desloratadine.

Renally impaired patients

The pharmacokinetics of desloratadine in patients with chronic renal insufficiency (CRI) was compared with that of healthy subjects in one single‑dose study and one multiple dose study. In the single‑dose study, the exposure to desloratadine was approximately 2 and 2.5‑fold greater in subjects with mild to moderate and severe CRI, respectively, than in healthy subjects. In the multiple‑dose study, steady state was reached after Day 11, and compared to healthy subjects the exposure to desloratadine was ~1.5‑fold greater in subjects with mild to moderate CRI and ~2.5‑fold greater in subjects with severe CRI. In both studies, changes in exposure (AUC and Cmax) of desloratadine and 3‑hydroxydesloratadine were not clinically relevant.

**5.3 Preclinical safety data**

Desloratadine is the primary active metabolite of loratadine. Non-clinical studies conducted with desloratadine and loratadine demonstrated that there are no qualitative or quantitative differences in the toxicity profile of desloratadine and loratadine at comparable levels of exposure to desloratadine.

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. The lack of carcinogenic potential was demonstrated in studies conducted with desloratadine and loratadine.

**6. PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

sorbitol,

propylene glycol,

sucralose E 955,

hypromellose 2910,

sodium citrate dihydrate,

natural and artificial flavour (bubblegum),

citric acid anhydrous,

disodium edetate,

purified water

**6.2 Incompatibilities**

Not applicable.

**6.3 Shelf life**

2 years

**6.4 Special precautions for storage**

Do not freeze. Store in the original package.

**6.5 Nature and contents of container**

Aerius oral solution, is supplied in 30, 50, 60, 100, 120, 150, 225 and 300 ml size Type III amber glass bottles closed with a plastic child resistant (C/R) screw closure having a multi-ply polyethylene-faced liner. All packages except the 150 ml package are supplied with a measuring spoon marked for doses of 2.5 ml and 5 ml. For the 150 ml package, a measuring spoon or an oral measuring syringe is provided, marked for doses of 2.5 ml and 5 ml.

Not all pack sizes may be marketed.

**6.6 Special precautions for disposal**

No special requirements.

**7. MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.

Waarderweg 39

2031 BN Haarlem

The Netherlands

**8. MARKETING AUTHORISATION NUMBERS**

EU/1/00/160/061-069

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 15 January 2001

Date of latest renewal: 15 January 2006

**10. DATE OF REVISION OF THE TEXT**

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.

### ANNEX II

1. **MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE**
2. **CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

**D. conditions or restrictions with regard to the safe and effective use of the medicinal product**

A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release for film-coated tablets

SP Labo N.V.

Industriepark 30

2220 Heist-op-den-Berg

Belgium

Name and address of the manufacturer responsible for batch release for orodispersible tablet

SP Labo N.V.

Industriepark 30

2220 Heist-op-den-Berg

Belgium

Name and address of the manufacturer responsible for batch release for oral solution

SP Labo N.V.

Industriepark 30

2220 Heist-op-den-Berg

Belgium

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

* **Periodic Safety Update Reports**

The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web‑portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

* **Risk Management Plan (RMP)**

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

* At the request of the European Medicines Agency;
* Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.

**ANNEX III**

**LABELLING AND PACKAGE LEAFLET**

A. LABELLING

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**BOX OF 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50, 90, 100 TABLETS**

**1. NAME OF THE MEDICINAL PRODUCT**

Aerius 5 mg film-coated tablets

desloratadine

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 5 mg desloratadine.

**3. LIST OF EXCIPIENTS**

Contains lactose.

See leaflet for further information.

**4. PHARMACEUTICAL FORM AND CONTENTS**

1 film-coated tablet

2 film-coated tablets

3 film-coated tablets

5 film-coated tablets

7 film-coated tablets

10 film-coated tablets

14 film-coated tablets

15 film-coated tablets

20 film-coated tablets

21 film-coated tablets

30 film-coated tablets

50 film-coated tablets

90 film-coated tablets

100 film-coated tablets

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Swallow the tablet whole with water.

Oral use

Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not store above 30°C. Store in the original package.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.

Waarderweg 39

2031 BN Haarlem

The Netherlands

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/00/160/001 1 tablet

EU/1/00/160/002 2 tablets

EU/1/00/160/003 3 tablets

EU/1/00/160/004 5 tablets

EU/1/00/160/005 7 tablets

EU/1/00/160/006 10 tablets

EU/1/00/160/007 14 tablets

EU/1/00/160/008 15 tablets

EU/1/00/160/009 20 tablets

EU/1/00/160/010 21 tablets

EU/1/00/160/011 30 tablets

EU/1/00/160/012 50 tablets

EU/1/00/160/036 90 tablets

EU/1/00/160/013 100 tablets

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Aerius

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC:

SN:

NN:

**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

**BOX OF 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50, 90, 100 TABLETS**

**1. NAME OF THE MEDICINAL PRODUCT**

Aerius 5 mg tablet

desloratadine

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

MSD

**3. EXPIRY DATE**

EXP

**4. BATCH NUMBER**

Lot

**5. OTHER**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**BOX OF 5, 6, 10, 12, 15, 18, 20, 30, 50, 60, 90, 100 ORODISPERSIBLE TABLETS**

**1. NAME OF THE MEDICINAL PRODUCT**

Aerius 2.5 mg orodispersible tablets

desloratadine

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each dose of orodispersible tablet contains 2.5 mg desloratadine.

**3. LIST OF EXCIPIENTS**

Contains mannitol and aspartame.

See leaflet for further information.

**4. PHARMACEUTICAL FORM AND CONTENTS**

5 orodispersible tablets

6 orodispersible tablets

10 orodispersible tablets

12 orodispersible tablets

15 orodispersible tablets

18 orodispersible tablets

20 orodispersible tablets

30 orodispersible tablets

50 orodispersible tablets

60 orodispersible tablets

90 orodispersible tablets

100 orodispersible tablets

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use

Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Store in the original package.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.

Waarderweg 39

2031 BN Haarlem

The Netherlands

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/00/160/037 5 orodispersible tablets

EU/1/00/160/038 6 orodispersible tablets

EU/1/00/160/039 10 orodispersible tablets

EU/1/00/160/040 12 orodispersible tablets

EU/1/00/160/041 15 orodispersible tablets

EU/1/00/160/042 18 orodispersible tablets

EU/1/00/160/043 20 orodispersible tablets

EU/1/00/160/044 30 orodispersible tablets

EU/1/00/160/045 50 orodispersible tablets

EU/1/00/160/046 60 orodispersible tablets

EU/1/00/160/047 90 orodispersible tablets

EU/1/00/160/048 100 orodispersible tablets

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Aerius 2.5 mg orodispersible tablet

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC:

SN:

NN:

**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

**1. NAME OF THE MEDICINAL PRODUCT**

Aerius 2.5 mg orodispersible tablets

desloratadine

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

MSD

**3. EXPIRY DATE**

EXP

**4. BATCH NUMBER**

Lot

**5. OTHER**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**BOX OF 5, 6, 10, 12, 15, 18, 20, 30, 50, 60, 90, 100 ORODISPERSIBLE TABLETS**

**1. NAME OF THE MEDICINAL PRODUCT**

Aerius 5 mg orodispersible tablets

desloratadine

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each dose of orodispersible tablet contains 5 mg desloratadine.

**3. LIST OF EXCIPIENTS**

Contains mannitol and aspartame.

See leaflet for further information.

**4. PHARMACEUTICAL FORM AND CONTENTS**

5 orodispersible tablets

6 orodispersible tablets

10 orodispersible tablets

12 orodispersible tablets

15 orodispersible tablets

18 orodispersible tablets

20 orodispersible tablets

30 orodispersible tablets

50 orodispersible tablets

60 orodispersible tablets

90 orodispersible tablets

100 orodispersible tablets

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use

Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Store in the original package.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.

Waarderweg 39

2031 BN Haarlem

The Netherlands

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/00/160/049 5 orodispersible tablets

EU/1/00/160/050 6 orodispersible tablets

EU/1/00/160/051 10 orodispersible tablets

EU/1/00/160/052 12 orodispersible tablets

EU/1/00/160/053 15 orodispersible tablets

EU/1/00/160/054 18 orodispersible tablets

EU/1/00/160/055 20 orodispersible tablets

EU/1/00/160/056 30 orodispersible tablets

EU/1/00/160/057 50 orodispersible tablets

EU/1/00/160/058 60 orodispersible tablets

EU/1/00/160/059 90 orodispersible tablets

EU/1/00/160/060 100 orodispersible tablets

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Aerius 5 mg orodispersible tablet

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC:

SN:

NN:

**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

**1. NAME OF THE MEDICINAL PRODUCT**

Aerius 5 mg orodispersible tablets

desloratadine

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

MSD

**3. EXPIRY DATE**

EXP

**4. BATCH NUMBER**

Lot

**5. OTHER**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**BOTTLE OF 30 ML, 50 ML, 60 ML, 100 ML, 120 ML, 150 ML, 225 ML, 300 ML**

**1. NAME OF THE MEDICINAL PRODUCT**

Aerius 0.5 mg/ml oral solution

desloratadine

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each ml of oral solution contains 0.5 mg desloratadine.

**3. LIST OF EXCIPIENTS**

Contains propylene glycol and sorbitol.

See leaflet for further information.

**4. PHARMACEUTICAL FORM AND CONTENTS**

oral solution

30 ml with 1 spoon

50 ml with 1 spoon

60 ml with 1 spoon

100 ml with 1 spoon

120 ml with 1 spoon

150 ml with 1 spoon

150 ml with 1 oral syringe

225 ml with 1 spoon

300 ml with 1 spoon

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use

Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Do not freeze. Store in the original package.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.

Waarderweg 39

2031 BN Haarlem

The Netherlands

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/00/160/061 30 ml with 1 spoon

EU/1/00/160/062 50 ml with 1 spoon

EU/1/00/160/063 60 ml with 1 spoon

EU/1/00/160/064 100 ml with 1 spoon

EU/1/00/160/065 120 ml with 1 spoon

EU/1/00/160/066 150 ml with 1 spoon

EU/1/00/160/069 150 ml with 1 oral syringe

EU/1/00/160/067 225 ml with 1 spoon

EU/1/00/160/068 300 ml with 1 spoon

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Aerius

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC:

SN:

NN:

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**BOTTLE OF 30 ML, 50 ML, 60 ML, 100 ML, 120 ML, 150 ML, 225 ML, 300 ML**

**1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION**

Aerius 0.5 mg/ml oral solution

desloratadine

**2. METHOD OF ADMINISTRATION**

Oral use

**3. EXPIRY DATE**

EXP

**4. BATCH NUMBER**

Lot

**5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT**

30 ml

50 ml

60 ml

100 ml

120 ml

150 ml

225 ml

300 ml

**6. LIST OF EXCIPIENTS**

Contains propylene glycol and sorbitol.

See leaflet for further information.

**7. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.

Waarderweg 39

2031 BN Haarlem

The Netherlands

**8. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**9. SPECIAL STORAGE CONDITIONS**

Do not freeze. Store in the original package.

B. PACKAGE LEAFLET

**Package leaflet: Information for the patient**

Aerius 5 mg film-coated tablets

desloratadine

**Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.**

1. Keep this leaflet. You may need to read it again.
2. If you have any further questions, ask your doctor, pharmacist or nurse.
3. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.

- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. **See section 4.**

**What is in this leaflet**

1. What Aerius is and what it is used for

2. What you need to know before you take Aerius

3. How to take Aerius

4. Possible side effects

5. How to store Aerius

6. Contents of the pack and other information

**1. What Aerius is and what it is used for**

**What Aerius is**

Aerius contains desloratadine which is an antihistamine.

**How Aerius works**

Aerius is an antiallergy medicine that does not make you drowsy. It helps control your allergic reaction and its symptoms.

**When Aerius should be used**

Aerius relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older. These symptoms include sneezing, runny or itchy nose, itchy palate, and itchy, red or watery eyes.

Aerius is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy). These symptoms include itching and hives.

Relief of these symptoms lasts a full day and helps you to resume your normal daily activities and sleep.

**2. What you need to know before you take Aerius**

**Do not take Aerius**

- if you are allergic to desloratadine, or any of the other ingredients of this medicine (listed in section 6) or to loratadine.

**Warnings and precautions**

Talk to your doctor, pharmacist or nurse before taking Aerius:

* if you have poor kidney function.
* if you have medical or familial history of seizures.

**Use in children and adolescents**

Do not give this medicine to children less than 12 years of age.

**Other medicines and Aerius**

There are no known interactions of Aerius with other medicines.

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

**Aerius with food, drink and alcohol**

Aerius may be taken with or without a meal.

Use caution when taking Aerius with alcohol.

**Pregnancy, breast-feeding and fertility**

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Taking Aerius is not recommended if you are pregnant or nursing a baby.

**Fertility**

There is no data available on male/female fertility.

**Driving and using machines**

At the recommended dose, this medicine is not expected to affect your ability to drive or use machines. Although most people do not experience drowsiness, it is recommended not to engage in activities requiring mental alertness, such as driving a car or operating machinery until you have established your own response to the medicinal product.

**Aerius contains lactose**

Aerius tablets contain lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

**3. How to take Aerius**

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

**Adults and adolescents 12 years of age and over**

The recommended dose is one tablet once a day with water, with or without food.

This medicine is for oral use.

Swallow the tablet whole.

Regarding the duration of treatment, your physician will determine the type of allergic rhinitis you are suffering from and will determine for how long you should take Aerius.

If your allergic rhinitis is intermittent (presence of symptoms for less than 4 days per week or for less than 4 weeks), your physician will recommend you a treatment schedule that will depend on the evaluation of the history of your disease.

If your allergic rhinitis is persistent (presence of symptoms for 4 days or more per week and for more than 4 weeks), your physician may recommend you a longer term treatment.

For urticaria, the duration of treatment may be variable from patient to patient and therefore you should follow the instructions of your physician.

**If you take more Aerius than you should**

Take Aerius only as it is prescribed for you. No serious problems are expected with accidental overdose. However, if you take more Aerius than you were told to, tell your doctor, pharmacist or nurse immediately.

**If you forget to take Aerius**

If you forget to take your dose on time, take it as soon as possible and then go back to your regular dosing schedule. Do not take a double dose to make up for a forgotten dose.

**If you stop taking Aerius**

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

**4. Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

During the marketing of Aerius, cases of severe allergic reactions (difficulty in breathing, wheezing, itching, hives and swelling) have been reported very rarely. If you notice any of these serious side effects, stop taking the medicine and seek urgent medical advice straight away.

In clinical studies in adults, side effects were about the same as with a dummy tablet. However, fatigue, dry mouth and headache were reported more often than with a dummy tablet. In adolescents, headache was the most commonly reported side effect.

In clinical studies with Aerius, the following side effects were reported as:

Common: the following may affect up to 1 in 10 people

● fatigue

● dry mouth

● headache

Adults

During the marketing of Aerius, the following side effects were reported as:

Very rare: the following may affect up to 1 in 10,000 people

● severe allergic reactions ● rash ● pounding or irregular heartbeat

● fast heartbeat ● stomach ache ● feeling sick (nausea)

● vomiting ● upset stomach ● diarrhoea

● dizziness ● drowsiness ● inability to sleep

● muscle pain ● hallucinations ● seizures

● restlessness with increased ● liver inflammation ● abnormal liver function tests

body movement

Not known: frequency cannot be estimated from the available data

● unusual weakness ● yellowing of the skin and/or eyes

● increased sensitivity of the skin to the sun, even in case of hazy sun, and to UV light, for instance to UV lights of a solarium

● changes in the way the heart beats

● abnormal behaviour

● aggression

● weight increased, increased appetite

Children

Not known: frequency cannot be estimated from the available data

● slow heartbeat ● change in the way the heart beats

● abnormal behaviour ● aggression

**Reporting of side effects**

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc). By reporting side effects you can help provide more information on the safety of this medicine.

**5. How to store Aerius**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.

Do not store above 30°C. Store in the original package.

Do not use this medicine if you notice any change in the appearance of the tablets.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

**6. Contents of the pack and other information**

**What Aerius contains**

* The active substance is desloratadine 5 mg
* The other ingredients of the tablet are calcium hydrogen phosphate dihydrate, microcrystalline cellulose, maize starch, talc. Tablet coating contains film coat (containing lactose monohydrate, hypromellose, titanium dioxide, macrogol 400, indigotin (E132)), clear coat (containing hypromellose, macrogol 400), carnauba wax, white wax.

**What Aerius looks like and contents of the pack**

Aerius 5 mg film-coated tablets are packed in blisters in packs of 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50, 90 or 100 tablets.

Not all pack sizes may be marketed.

**Marketing Authorisation Holder and Manufacturer**

Marketing Authorisation Holder:

Merck Sharp & Dohme B.V.

Waarderweg 39

2031 BN Haarlem

The Netherlands

Manufacturer: SP Labo N.V., Industriepark 30, B-2220 Heist-op-den-Berg, Belgium.

For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:

|  |  |
| --- | --- |
| **België/Belgique/Belgien**  MSD Belgium BVBA/SPRL  Tél/Tel: +32(0)27766211  dpoc\_belux@merck.com | **Lietuva**  UAB Merck Sharp & Dohme  Tel. + 370 5 278 02 47  msd\_lietuva@merck.com |
| **България**  Мерк Шарп и Доум България ЕООД  Тел.: +359 2 819 3737  info-msdbg@merck.com | **Luxembourg/Luxemburg**  MSD Belgium BVBA/SPRL  Tél/Tel: +32(0)27766211  dpoc\_belux@merck.com |
| **Česká republika**  Merck Sharp & Dohme s.r.o.  Tel: +420 233 010 111  dpoc\_czechslovak@merck.com | **Magyarország**  MSD Pharma Hungary Kft.  Tel.: +36 1 888 5300  hungary\_msd@merck.com |
| **Danmark**  Organon Denmark ApS  Tlf: + 45 4484 6800  info.denmark@organon.com | **Malta**  Merck Sharp & Dohme Cyprus Limited  Tel: 8007 4433 (+356 99917558)  malta**\_**info@merck**.**com |
| **Deutschland**  MSD SHARP & DOHME GMBH  Tel: 0800 673 673 673  (+49 (0) 89 4561 2612)  e-mail@msd.de | **Nederland**  Merck Sharp & Dohme B.V.  Tel: 0800 9999000 (+31 23 5153153)  medicalinfo.nl@merck.com |
| **Eesti**  Merck Sharp & Dohme OÜ  Tel: + 372 6144 200  msdeesti@merck.com | **Norge**  MSD (Norge) AS  Tlf: +47 32 20 73 00  msdnorge@msd.no |
| **Ελλάδα**  MSD Α.Φ.Β.Ε.Ε.  Τηλ: +30 210 98 97 300  dpoc\_greece@merck.com | **Österreich**  Merck Sharp & Dohme Ges.m.b.H.  Tel: +43 (0) 1 26 044  msd-medizin@merck.com |
| **España**  Organon Salud, S.L.  Tel: +34 91 591 12 79 | **Polska**  MSD Polska Sp. z o.o.  Tel: +48 22 549 51 00  msdpolska@merck.com |
| **France**  Organon France  Tél: + 33 (0) 1 57 77 32 00 | **Portugal**  Merck Sharp & Dohme, Lda  Tel: +351 21 4465700  inform\_pt@merck.com |
| **Hrvatska**  Merck Sharp & Dohme d.o.o.  Tel: + 385 1 6611 333  croatia\_info@merck.com | **România**  Merck Sharp & Dohme Romania S.R.L.  Tel: + 40 21 529 29 00  msdromania@merck.com |
| **Ireland**  Merck Sharp & Dohme Ireland (Human Health) Limited  Tel: +353 (0)1 2998700  medinfo\_ireland@merck.com | **Slovenija**  Merck Sharp & Dohme, inovativna zdravila d.o.o.  Tel: +386 1 5204 201  msd.slovenia@merck.com |
| **Ísland**  Vistor hf.  Sími: + 354 535 70 00 | **Slovenská republika**  Merck Sharp & Dohme, s. r. o.  Tel: +421 2 58282010  dpoc\_czechslovak@merck.com |
| **Italia**  MSD Italia S.r.l.  Tel: +39 06 361911  medicalinformation.it@merck.com | **Suomi/Finland**  MSD Finland Oy  Puh/Tel: + 358 (0)9 804 650  info@msd.fi |
| **Κύπρος**  Merck Sharp & Dohme Cyprus Limited  Τηλ.: 800 00 673  (+357 22866700)  cyprus\_info@merck.com | **Sverige**  Merck Sharp & Dohme (Sweden) AB  Tel: +46 77 5700488  medicinskinfo@merck.com |
| **Latvija**  SIA Merck Sharp & Dohme Latvija  Tel: + 371 67364224  msd\_lv@merck.com | **United Kingdom**  Merck Sharp & Dohme Limited  Tel: +44 (0) 1992 467272  medicalinformationuk@merck.com |

**This leaflet was last revised in**

Detailed information on this medicine is available on the European Medicines Agency website http://www.ema.europa.eu.

Package leaflet: Information for the patient

**Aerius 2.5 mg orodispersible tablets**

desloratadine

**Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.**

1. Keep this leaflet. You may need to read it again.
2. If you have any further questions, ask your doctor, pharmacist or nurse.
3. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
4. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. **See section 4.**

**What is in this leaflet**

1. What Aerius orodispersible tablet is and what it is used for

2. What you need to know before you take Aerius orodispersible tablet

3. How to take Aerius orodispersible tablet

4. Possible side effects

5. How to store Aerius orodispersible tablet

6. Contents of the pack and other information

**1. What Aerius orodispersible tablet is and what it is used for**

**What Aerius is**

Aerius contains desloratadine which is an antihistamine.

**How Aerius works**

Aerius orodispersible tablet is an antiallergy medicine that does not make you drowsy. It helps control your allergic reaction and its symptoms.

**When Aerius should be used**

Aerius orodispersible tablet relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults, adolescents and children 6 years of age and older. These symptoms include sneezing, runny or itchy nose, itchy palate, and itchy, red or watery eyes.

Aerius orodispersible tablet is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy). These symptoms include itching and hives.

Relief of these symptoms lasts a full day and helps you to resume your normal daily activities and sleep.

**2. What you need to know before you take Aerius orodispersible tablet**

**Do not take Aerius orodispersible tablet**

- if you are allergic to desloratadine, or any of the other ingredients of this medicine (listed in section 6) or to loratadine.

**Warnings and precautions**

Talk to your doctor, pharmacist or nurse before taking Aerius:

* if you have poor kidney function.
* if you have medical or familial history of seizures.

**Use in children and adolescents**

Do not give this medicine to children less than 6 years of age.

**Other medicines and Aerius**

There are no known interactions of Aerius with other medicines.

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

**Aerius orodispersible tablet with food, drink and alcohol**

Aerius orodispersible tablet does not need to be taken with water or liquid. Additionally, Aerius orodispersible tablet may be taken with or without a meal. Use caution when taking Aerius with alcohol.

**Pregnancy, breast-feeding and fertility**

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Taking Aerius is not recommended if you are pregnant or nursing a baby.

**Fertility**

There is no data available on male/female fertility.

**Driving and using machines**

At the recommended dose, this medicine is not expected to affect your ability to drive or use machines. Although most people do not experience drowsiness, it is recommended not to engage in activities requiring mental alertness, such as driving a car or operating machinery until you have established your own response to the medicinal product.

**Aerius orodispersible tablet contains aspartame**

This product contains aspartame. Aspartame is a source of phenylalanine, which may be harmful for people with phenylketonuria.

**3. How to take Aerius orodispersible tablet**

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

**Adults and adolescents 12 years of age and over**

The recommended dose is two tablets once a day with or without food.

This medicine is for oral use.

Before using, carefully peel open the blister and remove the dose of orodispersible tablet without crushing it. Place it in your mouth and it will disperse immediately. Water or other liquid is not needed to swallow the dose. Take the dose immediately after removal from the blister.

**Children from 6 to 11 years of age**

The recommended dose is one tablet once a day with or without food.

Regarding the duration of treatment, your physician will determine the type of allergic rhinitis you are suffering from and will determine for how long you should take Aerius orodispersible tablets.

If your allergic rhinitis is intermittent (presence of symptoms for less than 4 days per week or for less than 4 weeks), your physician will recommend you a treatment schedule that will depend on the evaluation of the history of your disease.

If your allergic rhinitis is persistent (presence of symptoms for 4 days or more per week and for more than 4 weeks), your physician may recommend you a longer term treatment.

For urticaria, the duration of treatment may be variable from patient to patient and therefore you should follow the instructions of your physician.

**If you take more Aerius orodispersible tablet than you should**

Take Aerius orodispersible tablet only as prescribed for you. No serious problems are expected with accidental overdose. However, if you take more Aerius orodispersible tablet than you were told to, tell your doctor, pharmacist or nurse immediately.

**If you forget to take Aerius orodispersible tablet**

If you forget to take your dose on time, take it as soon as possible and then go back to your regular dosing schedule. Do not take a double dose to make up for forgotten individual doses.

**If you stop taking Aerius orodispersible tablet**

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

**4. Possible side effects**

Like all medicines, this medicine can cause side effects although not everybody gets them.

During the marketing of Aerius, cases of severe allergic reactions (difficulty in breathing, wheezing, itching, hives and swelling) have been reported very rarely. If you notice any of these serious side effects, stop taking the medicine and seek urgent medical advice straight away.

In clinical studies in adults, side effects were about the same as with a dummy tablet. However, fatigue, dry mouth and headache were reported more often than with a dummy tablet. In adolescents, headache was the most commonly reported side effect.

In clinical studies with Aerius, the following side effects were reported as:

Common: the following may affect up to 1 in 10 people

● fatigue

● dry mouth

● headache

Adults

During the marketing of Aerius, the following side effects were reported as:

Very rare: the following may affect up to 1 in 10,000 people

● severe allergic reactions ● rash ● pounding or irregular heartbeat

● fast heartbeat ● stomach ache ● feeling sick (nausea)

● vomiting ● upset stomach ● diarrhoea

● dizziness ● drowsiness ● inability to sleep

● muscle pain ● hallucinations ● seizures

● restlessness with increased ● liver inflammation ● abnormal liver function tests

body movement

Not known: frequency cannot be estimated from the available data

● unusual weakness ● yellowing of the skin and/or eyes

● increased sensitivity of the skin to the sun, even in case of hazy sun, and to UV light, for instance to UV lights of a solarium

● changes in the way the heart beats

● abnormal behaviour

● aggression

● weight increased, increased appetite

Children

Not known: frequency cannot be estimated from the available data

● slow heartbeat ● change in the way the heart beats

● abnormal behaviour ● aggression

**Reporting of side effects**

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc). By reporting side effects you can help provide more information on the safety of this medicine.

**5. How to store Aerius orodispersible tablet**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.

Store in the original package.

Do not use this medicine if you notice any change in the appearance of Aerius orodispersible tablet.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

**6. Contents of the pack and other information**

**What Aerius orodispersible tablet contains**

1. The active substance is desloratadine 2.5 mg

- The other ingredients are microcrystalline cellulose, pregelatinized starch, sodium starch glycolate, magnesium stearate, butylated methacrylate copolymer, crospovidone, sodium hydrogen carbonate, citric acid, colloidal silicon dioxide, ferric oxide, mannitol, aspartame (E951) and flavour Tutti-Frutti.

**What Aerius orodispersible tablet looks like and contents of the pack**

Aerius 2.5 mg orodispersible tablet is light red, speckled, and round with “K” branded on one side. Aerius orodispersible tablet is packed in unit dose blisters in packs of 5, 6, 10, 12, 15, 18, 20, 30, 50, 60, 90 and 100 doses of orodispersible tablet. Not all pack sizes may be marketed.

**Marketing Authorisation Holder and Manufacturer**

Marketing Authorisation Holder:

Merck Sharp & Dohme B.V.

Waarderweg 39

2031 BN Haarlem

The Netherlands

Manufacturer: SP Labo N.V., Industriepark 30, B-2220 Heist-op-den-Berg, Belgium.

For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:

|  |  |
| --- | --- |
| **België/Belgique/Belgien**  MSD Belgium BVBA/SPRL  Tél/Tel: +32(0)27766211  dpoc\_belux@merck.com | **Lietuva**  UAB Merck Sharp & Dohme  Tel. + 370 5 278 02 47  msd\_lietuva@merck.com |
| **България**  Мерк Шарп и Доум България ЕООД  Тел.: +359 2 819 3737  info-msdbg@merck.com | **Luxembourg/Luxemburg**  MSD Belgium BVBA/SPRL  Tél/Tel: +32(0)27766211  dpoc\_belux@merck.com |
| **Česká republika**  Merck Sharp & Dohme s.r.o.  Tel: +420 233 010 111  dpoc\_czechslovak@merck.com | **Magyarország**  MSD Pharma Hungary Kft.  Tel.: +36 1 888 5300  hungary\_msd@merck.com |
| **Danmark**  Organon Denmark ApS  Tlf: + 45 4484 6800  info.denmark@organon.com | **Malta**  Merck Sharp & Dohme Cyprus Limited  Tel: 8007 4433 (+356 99917558)  malta**\_**info@merck**.**com |
| **Deutschland**  MSD SHARP & DOHME GMBH  Tel: 0800 673 673 673  (+49 (0) 89 4561 2612)  e-mail@msd.de | **Nederland**  Merck Sharp & Dohme B.V.  Tel: 0800 9999000 (+31 23 5153153)  medicalinfo.nl@merck.com |
| **Eesti**  Merck Sharp & Dohme OÜ  Tel: + 372 6144 200  msdeesti@merck.com | **Norge**  MSD (Norge) AS  Tlf: +47 32 20 73 00  msdnorge@msd.no |
| **Ελλάδα**  MSD Α.Φ.Β.Ε.Ε.  Τηλ: +30 210 98 97 300  dpoc\_greece@merck.com | **Österreich**  Merck Sharp & Dohme Ges.m.b.H.  Tel: +43 (0) 1 26 044  msd-medizin@merck.com |
| **España**  Organon Salud, S.L.  Tel: +34 91 591 12 79 | **Polska**  MSD Polska Sp. z o.o.  Tel: +48 22 549 51 00  msdpolska@merck.com |
| **France**  Organon France  Tél: + 33 (0) 1 57 77 32 00 | **Portugal**  Merck Sharp & Dohme, Lda  Tel: +351 21 4465700  inform\_pt@merck.com |
| **Hrvatska**  Merck Sharp & Dohme d.o.o.  Tel: + 385 1 6611 333  croatia\_info@merck.com | **România**  Merck Sharp & Dohme Romania S.R.L.  Tel: + 40 21 529 2900  msdromania@merck.com |
| **Ireland**  Merck Sharp & Dohme Ireland (Human Health) Limited  Tel: +353 (0)1 2998700  medinfo\_ireland@merck.com | **Slovenija**  Merck Sharp & Dohme, inovativna zdravila d.o.o.  Tel: +386 1 5204 201  msd.slovenia@merck.com |
| **Ísland**  Vistor hf.  Sími: + 354 535 70 00 | **Slovenská republika**  Merck Sharp & Dohme, s. r. o.  Tel: +421 2 58282010  dpoc\_czechslovak@merck.com |
| **Italia**  MSD Italia S.r.l.  Tel: +39 06 361911  medicalinformation.it@merck.com | **Suomi/Finland**  MSD Finland Oy  Puh/Tel: + 358 (0)9 804 650  info@msd.fi |
| **Κύπρος**  Merck Sharp & Dohme Cyprus Limited  Τηλ.: 800 00 673  (+357 22866700)  cyprus\_info@merck.com | **Sverige**  Merck Sharp & Dohme (Sweden) AB  Tel: +46 77 5700488  medicinskinfo@merck.com |
| **Latvija**  SIA Merck Sharp & Dohme Latvija  Tel: + 371 67364224  msd\_lv@merck.com | **United Kingdom**  Merck Sharp & Dohme Limited  Tel: +44 (0) 1992 467272  medicalinformationuk@merck.com |

**This leaflet was last revised in**

Detailed information on this medicine is available on the European Medicines Agency website http://www.ema.europa.eu.

Package leaflet: Information for the patient

**Aerius 5 mg orodispersible tablets**

desloratadine

**Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.**

1. Keep this leaflet. You may need to read it again.
2. If you have any further questions, ask your doctor, pharmacist or nurse.
3. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
4. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. **See section 4.**

**What is in this leaflet**

1. What Aerius orodispersible tablet is and what it is used for

2. What you need to know before you take Aerius orodispersible tablet

3. How to take Aerius orodispersible tablet

4. Possible side effects

5. How to store Aerius orodispersible tablet

6. Contents of the pack and other information

**1. What Aerius orodispersible tablet is and what it is used for**

**What Aerius is**

Aerius contains desloratadine which is an antihistamine.

**How Aerius works**

Aerius orodispersible tablet is an antiallergy medicine that does not make you drowsy. It helps control your allergic reaction and its symptoms.

**When Aerius should be used**

Aerius orodispersible tablet relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older. These symptoms include sneezing, runny or itchy nose, itchy palate, and itchy, red or watery eyes.

Aerius orodispersible tablet is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy). These symptoms include itching and hives.

Relief of these symptoms lasts a full day and helps you to resume your normal daily activities and sleep.

**2. What you need to know before you take Aerius orodispersible tablet**

**Do not take Aerius orodispersible tablet**

- if you are allergic to desloratadine, or any of the other ingredients of this medicine (listed in section 6) or to loratadine.

**Warnings and precautions**

Talk to your doctor, pharmacist or nurse before taking Aerius:

* if you have poor kidney function.
* if you have medical or familial history of seizures.

**Use in children and adolescents**

Do not give this medicine to children less than 12 years of age.

**Other medicines and Aerius**

There are no known interactions of Aerius with other medicines.

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

**Aerius orodispersible tablet with food, drink and alcohol**

Aerius orodispersible tablet does not need to be taken with water or liquid. Additionally, Aerius orodispersible tablet may be taken with or without a meal. Use caution when taking Aerius with alcohol.

**Pregnancy, breast-feeding and fertility**

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Taking Aerius is not recommended if you are pregnant or nursing a baby.

**Fertility**

There is no data available on male/female fertility.

**Driving and using machines**

At the recommended dose, this medicine is not expected to affect your ability to drive or use machines. Although most people do not experience drowsiness, it is recommended not to engage in activities requiring mental alertness, such as driving a car or operating machinery until you have established your own response to the medicinal product.

**Aerius orodispersible tablet contains aspartame**

This product contains aspartame. Aspartame is a source of phenylalanine, which may be harmful for people with phenylketonuria.

**3. How to take Aerius orodispersible tablet**

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

**Adults and adolescents 12 years of age and over**

The recommended dose is one tablet once a day with or without food.

This medicine is for oral use.

Before using, carefully peel open the blister and remove the dose of orodispersible tablet without crushing it. Place it in your mouth and it will disperse immediately. Water or other liquid is not needed to swallow the dose. Take the dose immediately after removal from the blister.

Regarding the duration of treatment, your physician will determine the type of allergic rhinitis you are suffering from and will determine for how long you should take Aerius orodispersible tablets.

If your allergic rhinitis is intermittent (presence of symptoms for less than 4 days per week or for less than 4 weeks), your physician will recommend you a treatment schedule that will depend on the evaluation of the history of your disease.

If your allergic rhinitis is persistent (presence of symptoms for 4 days or more per week and for more than 4 weeks), your physician may recommend you a longer term treatment.

For urticaria, the duration of treatment may be variable from patient to patient and therefore you should follow the instructions of your physician.

**If you take more Aerius orodispersible tablet than you should**

Take Aerius orodispersible tablet only as prescribed for you. No serious problems are expected with accidental overdose. However, if you take more Aerius orodispersible tablet than you were told to, tell your doctor, pharmacist or nurse immediately.

**If you forget to take Aerius orodispersible tablet**

If you forget to take your dose on time, take it as soon as possible and then go back to your regular dosing schedule. Do not take a double dose to make up for forgotten individual doses.

**If you stop taking Aerius orodispersible tablet**

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

**4. Possible side effects**

Like all medicines, this medicine can cause side effects although not everybody gets them.

During the marketing of Aerius, cases of severe allergic reactions (difficulty in breathing, wheezing, itching, hives and swelling) have been reported very rarely. If you notice any of these serious side effects, stop taking the medicine and seek urgent medical advice straight away.

In clinical studies in adults, side effects were about the same as with a dummy tablet. However, fatigue, dry mouth and headache were reported more often than with a dummy tablet. In adolescents, headache was the most commonly reported side effect.

In clinical studies with Aerius, the following side effects were reported as:

Common: the following may affect up to 1 in 10 people

● fatigue

● dry mouth

● headache

Adults

During the marketing of Aerius, the following side effects were reported as:

Very rare: the following may affect up to 1 in 10,000 people

● severe allergic reactions ● rash ● pounding or irregular heartbeat

● fast heartbeat ● stomach ache ● feeling sick (nausea)

● vomiting ● upset stomach ● diarrhoea

● dizziness ● drowsiness ● inability to sleep

● muscle pain ● hallucinations ● seizures

● restlessness with increased ● liver inflammation ● abnormal liver function tests

body movement

Not known: frequency cannot be estimated from the available data

● unusual weakness ● yellowing of the skin and/or eyes

● increased sensitivity of the skin to the sun, even in case of hazy sun, and to UV light, for instance to UV lights of a solarium

● changes in the way the heart beats

● abnormal behaviour

● aggression

● weight increased, increased appetite

Children

Not known: frequency cannot be estimated from the available data

● slow heartbeat ● change in the way the heart beats

● abnormal behaviour ● aggression

**Reporting of side effects**

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc). By reporting side effects you can help provide more information on the safety of this medicine.

**5. How to store Aerius orodispersible tablet**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.

Store in the original package.

Do not use this medicine if you notice any change in the appearance of Aerius orodispersible tablet.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

**6. Contents of the pack and other information**

**What Aerius orodispersible tablet contains**

1. The active substance is desloratadine 5 mg

- The other ingredients are microcrystalline cellulose, pregelatinized starch, sodium starch glycolate, magnesium stearate, butylated methacrylate copolymer, crospovidone, sodium hydrogen carbonate, citric acid, colloidal silicon dioxide, ferric oxide, mannitol, aspartame (E951) and flavour Tutti-Frutti.

**What Aerius orodispersible tablet looks like and contents of the pack**

Aerius 5 mg orodispersible tablet is light red, speckled, and round with “A” branded on one side. Aerius orodispersible tablet is packed in unit dose blisters in packs of 5, 6, 10, 12, 15, 18, 20, 30, 50, 60, 90 and 100 doses of orodispersible tablet.

Not all pack sizes may be marketed.

**Marketing Authorisation Holder and Manufacturer**

Marketing Authorisation Holder:

Merck Sharp & Dohme B.V.

Waarderweg 39

2031 BN Haarlem

The Netherlands

Manufacturer: SP Labo N.V., Industriepark 30, B-2220 Heist-op-den-Berg, Belgium.

For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:

|  |  |
| --- | --- |
| **België/Belgique/Belgien**  MSD Belgium BVBA/SPRL  Tél/Tel: +32(0)27766211  dpoc\_belux@merck.com | **Lietuva**  UAB Merck Sharp & Dohme  Tel. + 370 5 278 02 47  msd\_lietuva@merck.com |
| **България**  Мерк Шарп и Доум България ЕООД  Тел.: +359 2 819 3737  info-msdbg@merck.com | **Luxembourg/Luxemburg**  MSD Belgium BVBA/SPRL  Tél/Tel: +32(0)27766211  dpoc\_belux@merck.com |
| **Česká republika**  Merck Sharp & Dohme s.r.o.  Tel: +420 233 010 111  dpoc\_czechslovak@merck.com | **Magyarország**  MSD Pharma Hungary Kft.  Tel.: +36 1 888 5300  hungary\_msd@merck.com |
| **Danmark**  Organon Denmark ApS  Tlf: + 45 4484 6800  info.denmark@organon.com | **Malta**  Merck Sharp & Dohme Cyprus Limited  Tel: 8007 4433 (+356 99917558)  malta**\_**info@merck**.**com |
| **Deutschland**  MSD SHARP & DOHME GMBH  Tel: 0800 673 673 673  (+49 (0) 89 4561 2612)  e-mail@msd.de | **Nederland**  Merck Sharp & Dohme B.V.  Tel: 0800 9999000 (+31 23 5153153)  medicalinfo.nl@merck.com |
| **Eesti**  Merck Sharp & Dohme OÜ  Tel: + 372 6144 200  msdeesti@merck.com | **Norge**  MSD (Norge) AS  Tlf: +47 32 20 73 00  msdnorge@msd.no |
| **Ελλάδα**  MSD Α.Φ.Β.Ε.Ε.  Τηλ: +30 210 98 97 300  dpoc\_greece@merck.com | **Österreich**  Merck Sharp & Dohme Ges.m.b.H.  Tel: +43 (0) 1 26 044  msd-medizin@merck.com |
| **España**  Organon Salud, S.L.  Tel: +34 91 591 12 79 | **Polska**  MSD Polska Sp. z o.o.  Tel: +48 22 549 51 00  msdpolska@merck.com |
| **France**  Organon France  Tél: + 33 (0) 1 57 77 32 00 | **Portugal**  Merck Sharp & Dohme, Lda  Tel: +351 21 4465700  inform\_pt@merck.com |
| **Hrvatska**  Merck Sharp & Dohme d.o.o.  Tel: + 385 1 6611 333  croatia\_info@merck.com | **România**  Merck Sharp & Dohme Romania S.R.L.  Tel: + 40 21 529 29 00  msdromania@merck.com |
| **Ireland**  Merck Sharp & Dohme Ireland (Human Health) Limited  Tel: +353 (0)1 2998700  medinfo\_ireland@merck.com | **Slovenija**  Merck Sharp & Dohme, inovativna zdravila d.o.o.  Tel: +386 1 5204 201  msd.slovenia@merck.com |
| **Ísland**  Vistor hf.  Sími: + 354 535 7000 | **Slovenská republika**  Merck Sharp & Dohme, s. r. o.  Tel: +421 2 58282010  dpoc\_czechslovak@merck.com |
| **Italia**  MSD Italia S.r.l.  Tel: +39 06 361911  medicalinformation.it@merck.com | **Suomi/Finland**  MSD Finland Oy  Puh/Tel: + 358 (0)9 804 650  info@msd.fi |
| **Κύπρος**  Merck Sharp & Dohme Cyprus Limited  Τηλ.: 800 00 673  (+357 22866700)  cyprus\_info@merck.com | **Sverige**  Merck Sharp & Dohme (Sweden) AB  Tel: +46 77 5700488  medicinskinfo@merck.com |
| **Latvija**  SIA Merck Sharp & Dohme Latvija  Tel: + 371 67364224  msd\_lv@merck.com | **United Kingdom**  Merck Sharp & Dohme Limited  Tel: +44 (0) 1992 467272  medicalinformationuk@merck.com |

This leaflet was last revised in

Detailed information on this medicine is available on the European Medicines Agency website http://www.ema.europa.eu.

**Package leaflet: Information for the patient**

Aerius 0.5 mg/ml oral solution

desloratadine

**Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.**

1. Keep this leaflet. You may need to read it again.
2. If you have any further questions, ask your doctor, pharmacist or nurse.
3. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
4. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. **See section 4.**

**What is in this leaflet**

1. What Aerius oral solution is and what it is used for

2. What you need to know before you take Aerius oral solution

3. How to take Aerius oral solution

4. Possible side effects

5. How to store Aerius oral solution

6. Contents of the pack and other information

**1. What Aerius oral solution is and what it is used for**

**What Aerius is**

Aerius contains desloratadine which is an antihistamine.

**How Aerius works**

Aerius oral solution is an antiallergy medicine that does not make you drowsy. It helps control your allergic reaction and its symptoms.

**When Aerius should be used**

Aerius oral solution relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults, adolescents and children 1 year of age and older. These symptoms include sneezing, runny or itchy nose, itchy palate, and itchy, red or watery eyes.

Aerius oral solution is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy). These symptoms include itching and hives.

Relief of these symptoms lasts a full day and helps you to resume your normal daily activities and sleep.

**2. What you need to know before you take Aerius oral solution**

**Do not take Aerius oral solution**

- if you are allergic to desloratadine, or to any of the other ingredients of this medicine (listed in section 6) or to loratadine.

**Warnings and precautions**

Talk to your doctor, pharmacist or nurse before taking Aerius:

* if you have poor kidney function.
* if you have medical or familial history of seizures.

**Use in children and adolescents**

Do not give this medicine to children less than 1 year of age.

**Other medicines and Aerius**

There are no known interactions of Aerius with other medicines.

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

**Aerius oral solution with food, drink and alcohol**

Aerius may be taken with or without a meal.

Use caution when taking Aerius with alcohol.

**Pregnancy, breast-feeding and fertility**

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Taking Aerius oral solution is not recommended if you are pregnant or nursing a baby.

**Fertility**

There is no data available on male/female fertility.

**Driving and using machines**

At the recommended dose, this medicine is not expected to affect your ability to drive or use machines. Although most people do not experience drowsiness, it is recommended not to engage in activities requiring mental alertness, such as driving a car or operating machinery until you have established your own response to the medicinal product.

**Aerius oral solution contains sorbitol**

Aerius oral solution contains sorbitol. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

**3. How to take Aerius oral solution**

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

**Children**

Children 1 through 5 years of age:

The recommended dose is 2.5 ml (½ of a 5 ml spoonful) of oral solution once a day.

Children 6 through 11 years of age:

The recommended dose is 5 ml (one 5 ml spoonful) of oral solution once a day.

**Adults and adolescents 12 years of age and over**

The recommended dose is 10 ml (two 5 ml spoonfuls) of oral solution once a day.

In case an oral measuring syringe is provided with the bottle of oral solution, you can alternatively use it to take the appropriate amount of oral solution.

This medicine is for oral use.

Swallow the dose of oral solution and then drink some water. You can take this medicine with or without food.

Regarding the duration of treatment, your physician will determine the type of allergic rhinitis you are suffering from and will determine for how long you should take Aerius oral solution.

If your allergic rhinitis is intermittent (presence of symptoms for less than 4 days per week or for less than 4 weeks), your physician will recommend you a treatment schedule that will depend on the evaluation of the history of your disease.

If your allergic rhinitis is persistent (presence of symptoms for 4 days or more per week and for more than 4 weeks), your physician may recommend you a longer term treatment.

For urticaria, the duration of treatment may be variable from patient to patient and therefore you should follow the instructions of your physician.

**If you take more Aerius oral solution than you should**

Take Aerius oral solution only as it is prescribed for you. No serious problems are expected with accidental overdose. However, if you take more Aerius oral solution than you were told to, tell your doctor, pharmacist or nurse immediately.

**If you forget to take Aerius oral solution**

If you forget to take your dose on time, take it as soon as possible and then go back to your regular dosing schedule. Do not take a double dose to make up for a forgotten dose.

**If you stop taking Aerius oral solution**

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

**4.** **Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

During the marketing of Aerius, cases of severe allergic reactions (difficulty in breathing, wheezing, itching, hives and swelling) have been reported very rarely. If you notice any of these serious side effects, stop taking the medicine and seek urgent medical advice straight away.

In clinical studies in most children and adults, side effects with Aerius were about the same as with a dummy solution or tablet. However, common side effects in children less than 2 years of age were diarrhoea, fever and insomnia while in adults, fatigue, dry mouth and headache were reported more often than with a dummy tablet.

In clinical studies with Aerius, the following side effects were reported as:

Children

Common in children less than 2 years of age: the following may affect up to 1 in 10 children

● diarrhoea

● fever

● insomnia

Adults

Common: the following may affect up to 1 in 10 people

● fatigue

● dry mouth

● headache

During the marketing of Aerius, the following side effects were reported as:

Adults

Very rare: the following may affect up to 1 in 10,000 people

● severe allergic reactions ● rash ● pounding or irregular heartbeat

● fast heartbeat ● stomach ache ● feeling sick (nausea)

● vomiting ● upset stomach ● diarrhoea

● dizziness ● drowsiness ● inability to sleep

● muscle pain ● hallucinations ● seizures

● restlessness with increased ● liver inflammation ● abnormal liver function tests

body movement

Not known: frequency cannot be estimated from the available data

● unusual weakness ● yellowing of the skin and/or eyes

● increased sensitivity of the skin to the sun, even in case of hazy sun, and to UV light, for instance to UV lights of a solarium

● changes in the way the heart beats

● abnormal behaviour

● aggression

● weight increased, increased appetite

Children

Not known: frequency cannot be estimated from the available data

● slow heartbeat ● change in the way the heart beats

● abnormal behaviour ● aggression

**Reporting of side effects**

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc). By reporting side effects you can help provide more information on the safety of this medicine.

**5. How to store Aerius oral solution**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the bottle after EXP. The expiry date refers to the last day of that month.

Do not freeze. Store in the original package.

Do not use this medicine if you notice any change in the appearance of the oral solution.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

**6. Contents of the pack and other information**

**What Aerius oral solution contains**

1. The active substance is desloratadine 0.5 mg/ml
2. The other ingredients of the oral solution are sorbitol, propylene glycol, sucralose E 955, hypromellose 2910, sodium citrate dihydrate, natural and artificial flavour (bubblegum), citric acid anhydrous, disodium edetate and purified water.

**What Aerius oral solution looks like and contents of the pack**

Aerius oral solution is available in bottles of 30, 50, 60, 100, 120, 150, 225 and 300 ml, with a childproof cap. For all packages except the 150 ml bottle, a measuring spoon is provided, marked for doses of 2.5 ml and 5 ml. For the 150 ml package, a measuring spoon or an oral measuring syringe is provided, marked for doses of 2.5 ml and 5 ml.

Not all pack sizes may be marketed.

**Marketing Authorisation Holder and Manufacturer**

Marketing Authorisation Holder:

Merck Sharp & Dohme B.V.

Waarderweg 39

2031 BN Haarlem

The Netherlands

Manufacturer: SP Labo N.V., Industriepark 30, B-2220 Heist-op-den-Berg, Belgium.

For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:

|  |  |
| --- | --- |
| **België/Belgique/Belgien**  MSD Belgium BVBA/SPRL  Tél/Tel: +32(0)27766211  dpoc\_belux@merck.com | **Lietuva**  UAB Merck Sharp & Dohme  Tel. + 370 5 278 02 47  msd\_lietuva@merck.com |
| **България**  Мерк Шарп и Доум България ЕООД  Тел.: +359 2 819 3737  info-msdbg@merck.com | **Luxembourg/Luxemburg**  MSD Belgium BVBA/SPRL  Tél/Tel: +32(0)27766211  dpoc\_belux@merck.com |
| **Česká republika**  Merck Sharp & Dohme s.r.o.  Tel: +420 233 010 111  dpoc\_czechslovak@merck.com | **Magyarország**  MSD Pharma Hungary Kft.  Tel.: +36 1 888 5300  hungary\_msd@merck.com |
| **Danmark**  Organon Denmark ApS  Tlf: + 45 4484 6800  info.denmark@organon.com | **Malta**  Merck Sharp & Dohme Cyprus Limited  Tel: 8007 4433 (+356 99917558)  malta**\_**info@merck**.**com |
| **Deutschland**  MSD SHARP & DOHME GMBH  Tel: 0800 673 673 673  (+49 (0) 89 4561 2612)  e-mail@msd.de | **Nederland**  Merck Sharp & Dohme B.V.  Tel: 0800 9999000 (+31 23 5153153)  medicalinfo.nl@merck.com |
| **Eesti**  Merck Sharp & Dohme OÜ  Tel: +372 6144 200  msdeesti@merck.com | **Norge**  MSD (Norge) AS  Tlf: +47 32 20 73 00  msdnorge@msd.no |
| **Ελλάδα**  MSD Α.Φ.Β.Ε.Ε.  Τηλ: +30 210 98 97 300  dpoc\_greece@merck.com | **Österreich**  Merck Sharp & Dohme Ges.m.b.H.  Tel: +43 (0) 1 26 044  msd-medizin@merck.com |
| **España**  Organon Salud, S.L.  Tel: +34 91 591 12 79 | **Polska**  MSD Polska Sp. z o.o.  Tel: +48 22 549 51 00  msdpolska@merck.com |
| **France**  Organon France  Tél: + 33 (0) 1 57 77 32 00 | **Portugal**  Merck Sharp & Dohme, Lda  Tel: +351 21 4465700  inform\_pt@merck.com |
| **Hrvatska**  Merck Sharp & Dohme d.o.o.  Tel: + 385 1 6611 333  croatia\_info@merck.com | **România**  Merck Sharp & Dohme Romania S.R.L.  Tel: + 40 21 529 29 00  msdromania@merck.com |
| **Ireland**  Merck Sharp & Dohme Ireland (Human Health) Limited  Tel: +353 (0)1 2998700  medinfo\_ireland@merck.com | **Slovenija**  Merck Sharp & Dohme, inovativna zdravila d.o.o.  Tel: +386 1 5204 201  msd.slovenia@merck.com |
| **Ísland**  Vistor hf.  Sími: + 354 535 7000 | **Slovenská republika**  Merck Sharp & Dohme, s. r. o.  Tel: +421 2 58282010  dpoc\_czechslovak@merck.com |
| **Italia**  MSD Italia S.r.l.  Tel: +39 06 361911  medicalinformation.it@merck.com | **Suomi/Finland**  MSD Finland Oy  Puh/Tel: + 358 (0)9 804 650  info@msd.fi |
| **Κύπρος**  Merck Sharp & Dohme Cyprus Limited  Τηλ.: 800 00 673  (+357 22866700)  cyprus\_info@merck.com | **Sverige**  Merck Sharp & Dohme (Sweden) AB  Tel: +46 77 5700488  medicinskinfo@merck.com |
| **Latvija**  SIA Merck Sharp & Dohme Latvija  Tel: + 371 67364224  msd\_lv@merck.com | **United Kingdom**  Merck Sharp & Dohme Limited  Tel: +44 (0) 1992 467272  medicalinformationuk@merck.com |

**This leaflet was last revised in**

Detailed information on this medicine is available on the European Medicines Agency website http://www.ema.europa.eu.